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 CHAPTER I – INTRODUCTION 
 
1. Von Willebrand Factor (VWF) 
Von Willebrand factor (VWF) was first identified as an adhesive glycoprotein involved in haemostasis 
by Zimmerman in 1971 (1). Since then, two main haemostatic functions of VWF have been 
recognized. These are to mediate platelet adhesion and aggregation in the vessel wall, and to serve 
as a carrier and stabilizer of factor VIII in the circulation system (2). Both the size and the 
conformation of VWF are fundamental for its function and finely regulated by several mechanisms, 
including the cleavage by the metalloprotease ADAMTS13 under shear stress forces. Defects in VWF 
assembly, secretion and/or regulation of its activity lead to two diseases, opposite in their 
hemorrhagic and thrombotic nature: von Willebrand disease (VWD) and thrombotic 
thrombocytopenic purpura (TTP). VWD is the most common inherited human bleeding disorder and 
results from defects in plasma VWF quantity and/or quality (3). TTP is a thrombotic microangiopathic 
disorder associated with the spontaneous VWF-dependent platelet adhesion and aggregation, owing 
to hereditary or acquired deficiency of the VWF-cleaving protease, the metalloprotease ADAMTS13 
(4). 
 
Figure 1. Scheme of von Willebrand factor monomer molecule with its functional domains. The cleavage site of 
ADAMTS13 and the binding sites for factor VIII (FVIII), platelet glycoprotein Ibα (GPIbα), collagen and integrin αIIbβIII are 
indicated. 
     
1.1. Synthesis and secretion of VWF 
VWF is an abundant plasma glycoprotein synthesized in all vascular endothelial cells and 
megakaryocytes as a precursor containing a signal peptide, a large propeptide and several 
structurally defined domains, each with specific function, arranged in the order of D1-D2-D3’-A1-A2-
A3-D4-B1-B2-B3-C1-C2-CK  (5, 6) (Figure 1). The D1 and D2 domains comprise the propeptide and are 
2813
Multimers
S-S
Dimers
S-S
1-22 763
Propeptide FVIII GPIbα Collagen αIIbβIII
B
D1 D2 D’ D3 D4 C1 C2 CN CKA1 A2 A3 123
Cleavage site of ADAMTS13 
(Y1605-M1606)
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cleaved during proteolytic processing to generate the mature VWF. The pre-pro-VWF is comprised of 
2813 amino acids (aa) which encompass a 22-aa signal peptide, a 741-aa large propeptide and a 
2050-aa mature subunit. Translocation of VWF into the endoplasmic reticulum is facilitated by the 
proteolytic processing of the signal peptide. In the endoplasmic reticulum, proVWF (275 kDa) forms 
dimers via disulfide bonds at the carboxyl terminus, in a process named “tail-to-tail” dimerization. 
The pro-VWF dimers are subsequently transported to the Golgi complex, where further modifications 
take place, such as the multimerization through an additional disulfide bond near the amino 
terminus of the mature subunit (“head-to-head” multimerization), the proteolytic removal of the 
large VWF propeptide by furin and the sulfation of N-linked oligosaccharides and O-linked 
glycosilation (7). The multimeric VWF produced by endothelial cells is either secreted constitutively 
or stored in highly ordered tubules within storage organelles named Weibel-Palade bodies, whereas 
VWF produced by megakaryocytes is stored in α-granules that are later partitioned into platelets (8). 
Secretion of stored VWF from endothelial cells occurs through both a constitutive and a regulated 
pathway, while platelets lack the regulatory pathway and, once stimulated, constitutively release 
VWF. Upon stimulation by a variety of agonists, such as thrombin, epinephrine and inflammatory 
cytokines, VWF is released from endothelial cells as ultra-large VWF (UL-VWF) multimers, which 
consist of several hundreds of VWF monomers and can reach 50000 kDa in size (7). Upon release 
from endothelial cells, UL-VWF multimers are kept on the cell surface through a molecular anchor 
whose identity remains a subject of debate, but both P-selectin and integrin αvβ3 have been 
implicated in in vitro studies on cultured endothelial cells (9, 10). The anchored UL-VWF multimers 
are believed to be rapidly cleaved by the metalloprotease ADAMTS13 (11), whose action appears to 
be critical in preventing thrombosis in the microvasculature. Without this cleavage, these UL-VWF 
could eventually form string-like structure that would rapidly recruit platelets and leukocytes to 
endothelial cells (11, 12). Under fluid shear stress, ADAMTS13 cleave UL-VWF strings at the peptide 
bond between Tyr1605 and Met1606 in the A2 domain to generate the range of VWF multimer sizes 
that normally circulate in the blood, from approximately 500 kDa to 20000 kDa (13).  
 
1.2. VWF role in thrombus formation 
Under physiological conditions, circulating platelets are recruited from the blood flow to injury sites, 
where they act to prevent excessive bleeding (14). To perform their haemostatic function, platelets 
have to bind irreversibly at site of vascular injury, opposing the blood flow adjacent to the luminal 
surface. VWF is essential in this process, especially at the high shear rate (above 500-1000 s-1) found 
in small arterioles and capillaries, where it creates a bridge between platelets and the subendothelial 
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surface and acts to hold platelets together transiently until activation makes the platelet plug stable 
(15). 
When a vessel membrane is injured and the sub-endothelial components are exposed, the secreted 
UL-VWF is in part bound locally to endothelial cells and partly to the exposed collagen through its A3 
domain (Figure 2). Hydrodynamic forces cause conformational changes in VWF that expose its 
binding site in the A1 domain for platelet GPIbα, allowing platelets to attach and roll on the 
subendothelium. During this slow translocation, the continuous contact between platelets and VWF 
induces an activation process and another platelet surface receptor (integrin αIIbβ3 or GPIIb-IIIa) 
becomes available. This receptor is also able to interact with VWF with a tight binding, which arrests 
the rolling of platelets and stabilizes their adhesion to the damaged sub-endothelium (Figure 2A). 
Once platelets are immobilized to sites of vascular injury, they are activated by a range of agonists 
released or generated locally (such as collagen and thrombin). Platelet activation results in 
cytoskeleton and membrane changes/rearrangements associated with changes in platelet shape, 
from a discoid into a spherical, extrusion of extensive pseudopodia that help anchoring and exposure 
of negatively charged phospholipids for optimal binding of coagulation factors. The first layer of 
stable activated platelets becomes the substrate for accumulation of more platelets and thrombus 
growth (Figure 2B). Adhesive ligands, mainly fibrinogen and VWF, bind via activated GPIIb-IIIa on the 
membrane of the adherent platelets and become the substrate for the additional recruitment and 
attachment of incoming platelets. Also in this phase of thrombus growth, the high shear rate makes 
crucial the role of VWF since its multimeric conformation confers resistance to rheological forces of 
the circulating blood. 
 
 
 
Figure 2. Schematic representation of the mechanisms of platelet adhesion (A) and aggregation (B) in flowing blood. 
Modified from (15). 
  
A B
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1.3. Regulation of VWF size and conformation 
The biological function of VWF depends largely on the size of its multimers. Larger multimers contain 
multiple sites of interaction with platelets and vessel wall components and undergo more marked 
conformational changes in response to high shear stress (53). A shear stress is defined as the force 
that is applied parallel or tangential to the face of a material or molecule, as opposed to normal 
stress, which is applied perpendicularly. Under normal flowing conditions, VWF multimers circulate 
in a “globular” form that does not bind tightly to GPIbα and is not cleaved by ADAMTS13. Fluid 
shear-stress changes the conformation of VWF from a globular shape to an elongated rope-like 
structure (16, 17) so that it binds to platelet GPIbα tightly and can be cleaved by ADAMTS13. A 
similar modulating effect can be induced in vitro by using the antibiotic ristocetin or denaturating 
agents as urea and guanidine-HCl (13, 18). Moreover, shear-dependent changes in VWF promote 
VWF self-association and multimerization, resulting in the formation of fibrillar VWF structures that 
are activated in binding platelets (19, 20).  
The multimeric size of VWF has been shown to be regulated by a disulfide bond reducing activity 
associated with thrombospondin-1 (TSP-1) (21, 22). As VWF, TSP-1 is released by endothelial cells 
and megakaryocytes and tethers to sites of vascular damage. TSP-1 can then alter multimer size of 
proximal VWF molecules by splitting the disulfide-bonds that link VWF monomers at its N- and/or 
C-terminal ends; in addition, TSP-1 can compete with ADAMTS13 for the same VWF binding site in A2 
and A3 domains (23) and has been shown to protect VWF from degradation by ADAMTS13, both in in 
vitro and in vivo (24). An inter-molecular disulfide bond reduction of VWF multimers has also been 
reported by ADAMTS13 under high shear conditions, suggesting a mechanism that might reduce 
self-association of plasma VWF multimers to fibrillar structures with enhanced binding to platelets 
(25).  
Under fluid shear stress, the size of VWF is regulated by ADAMTS13 proteolysis. The unraveling of 
VWF due to high shear stress exposes the Tyr1605-Met1606 peptide bond in the A2 domain to 
ADAMTS13-mediated proteolysis. The VWF A2 domain crystal structure revealed a very rare vicinal 
disulphide bond between adjacent Cys1669 and Cys1670 at the C-terminus of the A2 domain, that 
contribute to form a “molecular plug” that directly interacts with hydrophobic residues in the core of 
the domain and stabilizing its fold. When VWF encounters elevated rheologic shear forces, this 
“molecular plug” is pulled out, allowing water molecules to enter and destabilize the hydrophobic 
core resulting in VWF A2 domain unfolding (26).  
Under similar conditions, leukocyte proteinases including elastase, cathepsin G, matrix 
metalloprotease 9 and proteinase 3 are also known to clip VWF at or near the Tyr1605 - Met1606 
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bond (27, 28), although the in vivo relevance of these proteases in VWF multimers regulation is 
currently unknown. 
Very recently, another protease belonging to the ADAM family of metalloproteases, ADAM28, has 
been shown to bind and cleave VWF, either in its native or unfolded conformation (29). ADAM28 is 
overexpressed in human cancers and associated with tumor growth and progression (30, 31) and 
may be involved in the degradation of VWF under pathological, rather than physiological conditions. 
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2. The metalloprotease ADAMTS13 
As already stated, VWF platelet-tethering function depends on VWF multimeric size. The largest VWF 
multimers show an enhanced haemostatic potential. Consequently, the size of plasma VWF 
multimers needs to be physiologically regulated to prevent abnormal thrombus formation. This is 
finely modulated by the plasma metalloprotease ADAMTS13, which cleaves VWF between Tyr1605 
and Met1606 within the A2 domain (13, 32). Mature ADAMTS13 is a 190 kDa zinc protease, which 
circulates in plasma as a constitutively active enzyme with a concentration of 1 μg/ml (~5 nM) and an 
estimated half life of two or three days (33-35). 
ADAMTS13 was first identified in 1996 (13, 18) and initially called VWF-cleaving protease, due to its 
function of regulating VWF multimeric size. A few years later, following its cloning, purification and 
domain structure characterization, it was classified as the 13th member of the ADAMTS (A 
Disintegrin and Metalloprotease with TromboSpondin motif) metalloproteinase family (34-37), which 
is related to the large ADAM (A Disintegrin And Metalloprotease) family. The ADAMTS family of zinc 
metalloproteases contains 19 members that share the common structure of a hydrophobic signal 
sequence, a propeptide, a metalloprotease domain, a disintegrin-like domain, a thrombospondin 
type 1 (TSP1) repeat, a cysteine-rich domain, and a spacer domain (35, 36). In contrast to ADAM 
proteases, ADAMTSs lack EGF-like repeats and a transmembrane domain and therefore are secreted 
rather than membrane-bound enzymes. In addition, all ADAMTS family members possess one or 
more thrombospondin type 1 (TSP1) motifs (38) and variable additional C-terminal domains. The 
carboxyl terminus of ADAMTS13 contains seven more TSP1 repeats and two CUB domains, which are 
named after motifs first identified in Complement components C1r and C1s, sea urchin protein Uegf, 
and Bone morphogenetic protein-1 (39) (Figure 3). 
 
CHAPTER I - INTRODUCTION 
7 
 
 
Figure 3. Schematic diagram of ADAM, ADAMTS and ADAMTS13 structure. The structural domains are indicated: signal 
peptide (S), propeptide (P), metalloprotease (M) (location of zinc-binding motif shown in red), disintegrin-like domain (Dis), 
first thrombospondin type 1 (TSP1) repeat (1), cysteine-rich domain (Cys-R), spacer domain (Spacer), the second to eighth 
TSP1 repeats (2-8) and two CUB domains (CUB1 and CUB2). The metalloprotease domain is the catalytic center that cleaves 
von Willebrand factor (VWF) The proximal carboxyl-terminal domains from Dis to Spacer interact with the A2 domain of 
VWF. More distal carboxyl-terminal domains interact with VWF under fluid shear stress. Interactions with globular VWF and 
endothelial cells have been mapped to the distal TSP1 repeats. EGF indicates epidermal growth factor-like repeat and TM 
indicates transmembrane domain. 
 
2.1. ADAMTS13 gene, synthesis and secretion 
The human ADAMTS13 gene is located on chromosome 9 at position 9q34. It spans 37 kb and 
contains 29 exons (36). ADAMTS13 mRNA is approximately 5 kb and encodes a 1427 amino acid 
protein, with a predicted molecular weight of 145 kDa, differing from the observed molecular mass 
of purified plasma ADAMTS13 (180-200 kDa) (34, 40) due to extensive glycosylation (41). ADAMTS13 
is mainly synthesized in hepatic stellate cells (35, 42, 43) even though several later studies found 
ADAMTS13 mRNA and protein in megakaryocytes/platelets (44, 45) and endothelial cells (46). Given 
the large surface area of vascular beds, the endothelial cell-derived ADAMTS13 could be a major 
source of plasma ADAMTS13. A 2.4-kb alternative spliced product was also found in placenta and 
skeletal muscle (35). In endothelial cells, ADAMTS13 secretion is targeted to the vascular lumen, 
primarily mediated by an interaction between the CUB domains in ADAMTS13 and the detergent-
resistant and cholesterol-enriched lipid rafts in the apical side of cells (47, 48). Glycosilation regulates 
ADAMTS13 secretion. Disrupting O-fucosylation by mutating conserved serine residues in the 
C-terminal TSP1 repeats is reported to reduce ADAMTS13 secretion from transfected HEK293T cells 
(49), and N-glycosylation in the endoplasmic reticulum is also critical for the efficient secretion of 
P M Dis 1 CUB1 CN CUB2Cys-R SpacerS 2 3 4 5 6 7 8
P M DisN Cys-R TMS EGF Cytoplasmatic C
P M Dis 1N Cys-R SpacerS Variable C-terminal domain C
ADAM
ADAMTS
ADAMTS13
Cleaving
VWF
Interact with VWF-A2 domain
Interact with VWF under flow
Interact with globular VWF
Interact with endothelial cells
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ADAMTS13 (50). Differently from the other metalloproteinase, ADAMTS13 is constitutively secreted 
into blood as an active enzyme (51).  
 
2.2. ADAMTS13 structure  
The 1427 amino acids (aa) of the precursor of ADAMTS13 consists of a 33-aa signal peptide, a 41-aa 
propeptide, a metalloprotease domain, a Thrombospondin Type-1 (TSP1) repeat, a cystein-rich 
domain, a spacer domain, seven additional TSP1 repeats and two CUB domains (82) (Figure 3). In 
2009, the X-ray diffraction map of the recombinant ADAMTS13 fragment comprising the 
disintegrin-like domain (D), the first TSP1 repeat (T), the cysteine-rich domain (C) and the spacer 
domain (S) (DTCS) has been reported, providing a considerable wealth of data demonstrating the 
relevance of noncatalytic exosites of ADAMTS13 for molecular recognition and cleavage of VWF 
multimers (52) (Figure 4). 
 
Figure 4. ADAMTS13-VWF interactions. (A) 
Folded and unfolded structures of the VWFA2 
domain. The scissile peptide bond (Tyr1605-
Met1606) is buried within the protein core 
under static conditions (“A2 folded”). The C-
terminal region (residues 1596-1668, 
corresponding to the VWF73 peptide) (53) of 
the A2 domain must be unfolded to expose the 
scissile bond and the exosite-binding regions 
under shear-stress conditions (“A2 unfolded”). 
(B) ADAMTS13-MDTCS-VWF binding model. 
The molecular surface of the ADAMTS13-MDTCS 
model is shown in gray and the bound zinc ion is 
shown in yellow. Residues that mediate VWF 
binding are depicted and the exosites and the 
catalytic cleft are indicated by red and yellow 
dotted ellipsoids, respectively. The dotted green 
line represents a VWF molecule (residues 1596-
1668) bound to ADAMTS-MDTCS. Structural and functional data suggest that the catalytic cleft plus exosite-1 (MD), exosite-
2 (C), and exosite-3 (S) make cooperative, modular contacts with 3 discrete segments of the VWF A2 domain (see text for 
discussion). Adapted from (52). 
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2.2.1. Propeptide domain (residues 34-74)  
The ADAMTS13 propeptide is shorter (41 residues) compared with other ADAMTS family propeptides 
(about 200 aa). Like other metalloproteases, ADAMTS13 propeptide presents a typical proprotein 
processing site (RQRR), which has been shown to be a furin cleavage site (35). ADAMTS13 propeptide 
seems to be dispensable for normal folding, secretion or enzymatic activity, since deletion of the 
propeptide does not affect secretion of active enzyme (54). Moreover, it does not confer enzyme 
latency, as it has been shown that mutation in furin consensus recognition site leads to secretion of 
an active pro-ADAMTS13 (54). Finally, detection of anti-propeptide antibodies in some patients with 
TTP suggests that not all plasma ADAMTS13 has this sequence removed (55). 
2.2.2. Metalloprotease domain (residues 75-289) 
No detailed knowledge of the atomic structure of the metalloprotease domain of ADAMTS13 is 
available, but, thanks to the high degree of similarity with other ADAMTS proteinases, especially 
ADAMTS4 and 5, a three-dimensional model of ADAMTS13 metalloprotease domain was built by 
homology modeling techniques (56). The catalytic domain of ADAMTS13 contains the highly 
conserved zinc-binding sequence, in which the catalytic Zn2+ ion is coordinated by three histidine 
residues, “H224EXXHXXGXXHD235”, where “X” represents any amino acid residue and the aspartic acid 
distinguishes the ADAMs and ADAMTSs from other metalloproteinases. The glutamate following the 
first zinc-binding histidine has a catalytic role (57), polarizing through hydrogen bonding a water 
molecule, which is stabilized by coordination with the Zn2+ ion and it is responsible for the 
nucleophilic attack on the carbonyl of the substrate scissile peptide bond (58). The arrangement of 
the active site is facilitated by the conserved glycine 231, which permits a tight hairpin loop and 
enables the third histidine to occupy its correct position (59, 60). As in all metalloproteinases, the 
zinc-binding sequence is followed a short distance from the C-terminal end by a conserved 
methionine residue, that constitutes the so-called ‘‘Met-turn’’, a tight turn arranged as a right-
handed screw that seems to serve an important function in the structure of the active site (59). 
Recently, deletion and mutagenesis studies by Xiang et al. and de Groot et al. showed that Leu151 
and Val195, and Asp252-Pro256, are critical for VWF cleavage, as they probably shape the docking 
sites of VWF Tyr1605 and Met1606, respectively, contributing to scissile bond specificity (61, 62). 
Moreover, in the same mutagenesis study, residues Leu198, Leu232 and Leu274 have been identified 
as elements that together may make up another crucial subsite accommodating VWF Leu1603 which 
has an essential role in proteolysis of the scissile bond (62). 
In addition to the Zn2+ ion in the active site, Ca2+ ions are also required for enzyme function. 
ADAMTS13 activity is cooperatively enhanced by the two ions and it is likely that ADAMTS13 
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circulating in normal plasma is fully saturated by both ions (63). The importance of zinc and calcium 
ions explains why ADAMTS13 function is completed inhibited by metal ions chelators, such as 
ethylenediaminetetraacetic acid (EDTA) (13). Two putative calcium binding sites (CaBSs), CaBS-I and 
CaBS-II can be identified in ADAMTS13. Through homology modeling techniques, Pozzi et al. recently 
showed that CaBS-I is formed by highly conserved aminoacids (Asp165, Asp173, Glu83) and by a 
connector loop consisting of Cys281 and Asp284 and can accommodate two Ca2+ ions (56). 
Alternatively, CaBS-II binds a single Ca2+ ion, is positioned opposite to CaBS-I, adjacent to the active 
site, and is formed by Asp182, Leu183, Arg190, Val192 and Glu212 (56). This model is consistent with 
biochemical and mutagenesis studies showing that ADAMTS13 contains a low-affinity CaBS-I (EC50 = 
880 µM), which is occupied by two Ca2+ ions and mainly exerts a structural role, and a high-affinity 
site (KD(app) = 70 µM), CaBS-II, which plays a functional role, as mutations in the involved residues 
increased the KD(app) by more than 10 fold (64). 
Different studies using C-terminal truncations of recombinant ADAMTS13 have shown that the 
metalloprotease domain alone was not able to cleave plasma VWF (65, 66) or a short A2 domain 
peptide, VWF73 (residues 1596-1668) (67). However, it was found that the metalloprotease domain 
alone could cleave the substrate after long incubation times (16-24 hours), but at a different site 
than the predicted Tyr1605-Met1606 (67), suggesting that the other downstream domains are 
responsible for determining substrate specificity of cleavage. 
2.2.3. Disintegrin-like domain (residues 290-385) 
Despite its name and high similarity with snake venom disintegrins, this domain does not actually 
have an RGD integrin binding sequence and it is not known to bind integrins. On the contrary, the 
crystal structure of the metalloprotease-disintegrin-like domains from other ADAMTS proteinases 
revealed a greater structural homology to cysteine-rich domains (52, 68, 69). Truncated ADAMTS13 
variants suggested the importance of the disintegrin-like domain for both enzyme activity and 
specificity (70). Moreover, targeted mutagenesis of nonconserved regions in this domain identified 
three residues, Arg349, Leu350 and Val352, important for ADAMTS13 proteolytic function (71). In 
particular, the authors proposed a model in which Arg349 and Leu350 in ADAMTS13 interact with 
Asp1614 and Ala1612 in VWF, assisting in positioning the Tyr1605-Met1606 bond into the active site 
cleft of ADAMTS13 (71). Recent structural data confirmed this model, individuating Arg349 as part of 
exosite-1, one of the three exosites whose interaction with VWF A2 domain is pivotal for its 
proteolytic processing by ADAMTS13 (52) (Figure 4). 
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2.2.4. Thrombospondin Type 1-Like (TSP1) Repeats 
ADAMTS13 has eight TSP1 repeats: the first one (residues 386-439) is located between the 
disintegrin-like domain and the Cys-rich domain; the other seven (residues 686-1131) are located 
between the spacer domain and the two C-terminal CUB domains. By analogy to thrombospondin 1 
and 2, TSP1 repeats may play a role in binding glycosaminoclycans and/or CD36, localizing 
ADAMTS13 to the surface of endothelial cells (72). Vomund and Majerus showed that ADAMTS13 
binds to endothelial cells in a specific manner (KD = 58 nM) and that the binding requires the 
C-terminal TSP1 repeats of the protease (73). Moreover, Davis et al. reported that recombinant 
human ADAMTS13 binds to both recombinant human CD36 and CD36 expressed on platelets 
membrane in vitro (74). Taken together, these data suggest that the interaction between ADAMTS13 
TSP1 repeats and CD36, or some other still unidentified receptor on endothelial cells and platelets, 
might localize ADAMTS13 at the endothelium surface, where cleavage of VWF multimers mainly 
occurs. Furthermore, supporting this hypothesis, anti-CD36 antibodies have been frequently found in 
patients with acquired TTP (75, 76). Finally, two groups independently showed that the C-terminal 
TSP1 repeats, TSP5-8, mediate the binding to the C-terminal domains of VWF in its 
quiescent/globular conformation (77, 78) (see section 2.3). 
2.2.5. Cys-rich domain (residues 440-555) 
This domain is a well-conserved, rich in cysteines domain, with 10 cysteine residues. The importance 
of this domain is highlighted by the identification of a polymorphism, Pro475Ser, in the Japanese 
population, that alters ADAMTS13 activity but not its secretion (41). Furthermore, a mutation found 
in a patient with inherited ADAMTS13 deficiency (Gln449stop) causing a premature stop after the 
first TSP1 repeat resulted in a truncated protein which was secreted normally, but possessed very 
low enzymatic activity (41). According to the DTCS crystal structure, the cys-rich domain contains a 
variable loop that might create another exosite (exosite-2) and mutations in the involved residues 
resulted in very low enzymatic activity (52) (Figure 4).  
2.2.6. Spacer domain (residues 556-685) 
This domain has been shown to be essential for efficient ADAMTS13 VWF-cleaving activity (65, 66). 
ADAMTS13 fragments truncated after the metalloprotease domain, the disintegrin domain, the first 
TSP1 repeat or the Cys-rich domain were not able to cleave full-length VWF, whereas addition of the 
spacer region restored protease activity (65, 66). Moreover, ADAMTS13 truncated after the first TSR 
bound full-length VWF with a KD of 206 nM whereas ADAMTS13 truncated after the spacer domain 
bound to it with a KD of 23 nM. This is comparable to the KD of 14 nM found for full-length 
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ADAMTS13 interaction with full-length VWF (54). Similar results were obtained testing the binding to 
the VWF peptide, VWF73: ADAMTS13 truncated after the spacer domain bound to VWF73 with a KD 
of 7 nM, comparable to that obtained using full-length ADAMTS13 (KD 4,6 nM), whereas further 
truncation drastically reduced the binding. Other studies reported that the spacer domain is able to 
bind a complementary site that includes residues Glu1660–Arg1668 at the carboxyl terminus of the 
A2 domain of VWF (52, 79, 80). Deleting the spacer domain from ADAMTS13 or deleting the 
carboxyl-terminal end of the A2 domain did indeed reduce the rate of cleavage by 20-fold (79). 
According to the DTCS crystal structure, the spacer domain contains a VWF-binding exosite (exosite-
3), comprising residues Tyr659-Tyr665 (52) (Figure 4). Substitution of Arg660, Tyr661 and Tyr665 
resulted in a 12-fold reduction in catalytic efficiency of peptide VWF proteolysis and a 25-fold 
reduction in its binding (81). Very recently, a region between residues Glu634 and Arg639 has been 
identified as a novel exosite necessary for recognition and cleavage of VWF and termed exosite 4 
(82). Further insight into the role of the spacer domain derives from the characterization of anti-
ADAMTS13 antibodies that arise in patients with acquired TTP. Indeed, nearly all adult idiopathic TTP 
patients with severely deficient plasma ADAMTS13 activity harbor polyclonal anti-ADAMTS13 
antibodies that bind the Cys-rich and spacer domains, particularly the spacer domain of ADAMTS13 
(65, 83-86). Recent studies have shown that exosite-3 (Tyr659-Tyr665) and several other adjacent 
amino acid residues (Arg568 and Phe592) in the spacer domain comprise a major antigenic epitope 
for anti-ADAMTS13 autoantibodies in idiopathic TTP (81, 87) (see section 4.3). If several 
modifications of these amino acids were found to impair VWF binding and cleaving by ADAMTS13 
(81, 88, 89), a combination of amino acidic substitutions at positions 568, 592, 660 and 661 
(Arg660Lys/Phe592Tyr/Arg568Lys/Tyr661Phe) generated an ADAMTS13 variant with dramatically 
enhanced specific activity toward VWF compared with wild type (89). These substitutions appear to 
increase hydrophobic interactions between exosite-3 in the spacer domain and VWF A2 domain, 
confirming once more the importance of the former in ADAMTS13-mediated proteolytic processing 
of VWF. 
2.2.7. CUB domains (residues 1192-1408) 
ADAMTS13 is the only member of the ADAMTS family to contain CUB domains, of which there are 
two located at the C-terminus. CUB domains are present on proteins known to be important for 
developmental regulation (39). CUB domains appear to determine ADAMTS13 secretion in 
endothelial cells, as their deletion abolishes the apical secretion of the enzyme in cell culture (47). 
Moreover, Zhou and colleagues have showed that naturally occurring mutations in the CUB-1 domain 
result in normal rates of synthesis, but lower rates of secretion to the luminal surface of transfected 
Hela cells (48). In a more recent study, the same authors demonstrated that cysteine residues in 
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CUB-1 domain are critical for ADAMTS13 secretion and stability, as conversion of cysteines 1192, 
1213, 1236 and 1254 into serine residues reduced the secretion of the mutants to the conditioned 
medium, but not to extracellular matrix and resulted in a moderate increase in proteolytic 
degradation (90). To date, the role of ADAMTS13 CUB domains in ADAMTS13 function is 
controversial. Four different studies using C-terminal truncations of ADAMTS13 have shown that 
these domains are not required for VWF-cleaving activity under static (65-67) and flow (91) 
conditions. However, the CUB domains, along with the C-terminal TSP, have been claimed to be 
important for optimal cleavage activity of ADAMTS13 under flow conditions (92), against full-length 
murine VWF (93), for cleaving platelet decorated strings (94) and modulating thrombus formation 
(95) in vivo. Moreover, competitive binding studies under flow conditions have found that 
recombinant CUB1 domain inhibited VWF proteolysis (96). Autoantibodies against the CUB domains 
have been found in about one third of patients with acquired TTP, but it is unknown whether they 
compromise ADAMTS13 function or lead to ADAMTS13 depletion by the formation of 
antibody-antigen complexes (55, 86). 
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2.3. Recognition and cleavage of VWF by ADAMTS13 
A fine balance between UL-VWF multimers and proteolysis is crucial to generate the VWF multimers 
forms that normally circulate in plasma and to maintain haemostasis under pathophysiological 
circumstances. Recognition of VWF by ADAMTS13 is complex, yet highly specific and involves 
multiple interactions between distinct domains of both ADAMTS13 and VWF, with some of the 
interaction sites on VWF only becoming exposed during shear. The fact that ADAMTS13, unlike the 
vast majority of haemostatic proteases, is a constitutively active secreted enzyme without any known 
specific inhibitor, and that VWF is its only known substrate, implies that VWF proteolysis is primarily 
regulated by the availability of the scissile bond of VWF and by the high specificity of the 
VWF-ADAMTS13 interaction. This lead to the intriguing concept that the regulation of VWF function 
(the substrate) by ADAMTS13 (the enzyme) is in turn controlled by the substrate itself and explain 
why so many efforts have been done to unravel the molecular mechanisms underlying the 
modulation of this central interaction over the past decade. 
2.3.1. ADAMTS13 binding to globular VWF 
As described above, much of the studies performed to investigate the molecular determinants of the 
interaction between VWF and ADAMTS13 exploited the generation of ADAMTS13 deletion mutants 
progressively truncated from the C-terminus. Despite the limitations of potential conformational 
changes induced by domain deletion, these mutants have provided valuable initial tools for exploring 
ADAMTS13 domain function. Early results established the importance of several exosites in the 
proximal C-terminal domains of ADAMTS13, in particular in the spacer domain, while providing 
inconsistent evidence for a functional role for the C-terminal TSRs and CUB domains. To address this 
issue, Zanardelli and colleagues prepared deletion mutants of both VWF and of ADAMTS13 and 
performed binding and activity studies under both static and flow conditions (77). These experiments 
showed that full-length ADAMTS13 bind with a KD of 86 nM to VWF in its globular conformation and 
that this binding is mediated in part by the VWF D4 domain and the TSP5-8 and/or the CUB domains 
of ADAMTS13. Similar conclusions were drawn by Feys and colleagues using immunoprecipitation of 
VWF-ADAMTS13 complexes in solution (78). The authors determined a KD of 79 nM and mapped the 
interaction in the ADAMTS13 TSP2-8 repeats. Both studies demonstrated the specific binding of 
ADAMTS13 to globular VWF and that, in the absence of shear-induced unfolding of VWF, this 
interaction is nonproductive in terms of VWF proteolysis. Importantly, Feys et al. demonstrated that 
about 3% of ADAMTS13 circulates bound to VWF in normal plasma. Even though this represents a 
small percentage of plasma ADAMTS13, this pool may be particularly effective at colocalizing VWF 
and ADAMTS13 to the site of vessel damage. Evidence that this may have a functional physiological 
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role was provided by Banno and collegues, who examined mice with an Adamts13 gene that 
expresses a truncated form of the enzyme (ADAMTS13S), lacking the TSP7-8 and CUB domains (95). 
Plasma VWF multimers from Adamts13S/S did not differ from those of Adamts13+/+ mice, suggesting 
that the TSP7-8 and the CUB domains may not be necessary for modulating normal plasma VWF size. 
However, mice expressing the truncated ADAMTS13 were more thrombogenic in experimental 
thrombus formation under high shear conditions, suggesting that the loss of the TSP7-8 and CUB 
domains impaired the ability of ADAMTS13 to regulate VWF-dependent development of the platelet 
plug. 
2.3.2. VWF proteolysis by ADAMTS13: a “molecular” zipper mode of action 
As described above, VWF circulates in its globular/ADAMTS13-resistant form until it encounters a site 
of vessel damage that has resulted in the exposure of subendothelial collagen to the flowing blood. A 
binding site for ADAMTS13 within the D4-CK domains of VWF is nevertheless constitutively exposed, 
and a small proportion of circulating ADAMTS13 can reversibly associate with it through its TSP5-CUB 
domains. Under high shear stress conditions (when tethered to the site of vessel injury by its A3 
domain, during passage through the microvasculature or when secreted), VWF undergoes a 
conformational change from its globular to its string-like conformation, exposing additional binding 
sites for exosites present in the proximal C-terminal domains of ADAMTS13 that collectively 
contribute to bring the scissile bond of VWF over the active site of the metalloprotease. First, an 
exosite comprising residues Arg660-Tyr665, Arg 568 and Phe 592 of ADAMTS13 spacer domain 
recognizes VWF residues Glu1660-Arg1668, revealed when the “molecular plug” is pulled out from 
the hydrophobic core of the A2 domain. Then, a variable loop in the Cys-rich domain of ADAMTS13 
interact with residues 1642-1652 of VWF, followed by the binding of Arg349 in ADAMTS13 
disintegrin-like domain to Asp1614 of VWF. Finally, essential contacts are made between the subsites 
in the metalloprotease domain of ADAMTS13 (involving Leu198, Leu232, Leu274, Leu151, Val195 and 
Asp252-Pro256) and VWF residues adjacent and composing the scissile bond (Leu1603, Tyr1605 and 
Met1606). All together, these interactions, that can be envisaged to represent a “molecular zipper”, 
position the scissile bond into the ADAMTS13 active site pocket, where cleavage takes place (97). 
2.3.3. Modulators of ADAMTS13 activity 
The unique requirement of shear forces and the multiple interactions of remote exosites on both the 
enzyme and the substrate finely regulates ADAMTS13 activity. These mechanisms appear to be 
sufficient to impede uncontrolled VWF proteolysis, as no physiological specific inhibitor of 
ADAMTS13 activity is known. However, its activity might be negatively modulated by other factors, 
such as chloride ions, some coagulation proteases, haemolysis products and inflammatory cytokines. 
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De Cristofaro et al. showed that binding of chloride ions at physiological concentrations to the A1 
domain of VWF induce conformational transitions in the A1-A2 VWF domains, which make the 
scissile bond unavailable to proteolysis by ADAMTS13 and that chloride affinity drastically decreased 
in the presence of ristocetin (98). The authors thus suggested that GPIbα binding could reverse the 
inhibitory effect of chloride ions, whose concentration gradient across the cell membrane may 
represent a physiological strategy to regulate ADAMTS13 enzymatic activity. Free haemoglobin (99, 
100) and interleukin-6 (101) have been shown to inhibit ADAMTS13 function, but their physiological 
significance is unclear and they may have a role only under pathophysiological circumstances. 
Thrombin, factor Xa, plasmin (102, 103) and leukocyte proteases (28) can cleave and inactivate 
ADAMTS13 through defined cleavage inactivation sites, and therefore might regulate ADAMTS13 
activity at sites of thrombus formation. However, as evidence of ADAMTS13 proteolysis in vivo has 
only been observed in patients with severe sepsis (104) or in a very rare case of 2-antiplasmin 
deficiency (105), it is probable that this remains a pathologic phenomenon rather than a normal 
control mechanism. 
On the other hand, ADAMTS13 proteolytic activity have been shown to be positively regulated by 
platelets (106, 107) and factor VIII (107-109), suggesting that the binding of platelet GPIbα and factor 
VIII to the specific regions of VWF may accelerate the conformational transitions under fluid shear 
stress, thereby allowing ADAMTS13 to access the scissile bond and reduce VWF multimers size. 
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3. Thrombotic thrombocytopenic purpura (TTP) 
 
3.1. History of TTP 
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy characterized by 
thrombocytopenia and haemolytic anemia due to disseminated microvascular thrombosis. TTP was 
first described in 1924 by Eli Moschcowitz at the Mount Sinai Hospital in New York City in a 
previously healthy 16-year-old girl who died after an acute illness presenting anemia, purpura, 
microscopic haematuria, and, at autopsy, disseminated microvascular thrombi (110). A similar 
disorder was reported in 1960 by Schulman et al. (111) and later on by Upshaw et al. (112). In 1966, 
the evaluation of 271 cases by Amorosi and Ultamann permitted this mysterious disease to be 
clinically established as a symptomatic pentad of signs and symptoms: anemia, thrombocytopenia, 
fever, hemiparesis and haematuria (113). It was postulated that massive thrombus formation in the 
terminal circulation was due to the presence of “poisonous substances” that aggregated platelets 
intravascularly but the putative toxic agent had remained unknown for a long time. A major 
breakthrough in understanding the pathogenesis of TTP was provided by Joel Moake and colleagues 
in 1982 when they observed that the plasma of a patient affected with TTP presented highly 
thrombogenic forms of the multimeric glycoprotein von Willebrand factor (VWF), a major adhesive 
protein contained in endothelial cells, platelets and plasma (114). The hypothesis that a deficiency of 
a cleaving protease was responsible for the presence of these particularly high molecular weight 
(ultra-large) VWF multimers was postulated by Moake, but it was not confirmed until 1996, when 
Furlan and Tsai independently isolated from human plasma a metal ion-dependent protease which 
cleaves the peptide bond between the tyrosine at position 1605 and the methionine at position 1606 
in the central A2 domain of VWF (115, 116). Furthermore, the VWF-cleaving protease was found to 
be deficient in patients affected with TTP (115-117). In 2001, this protease was identified by Zheng 
and colleagues as a new (the thirteenth) member of the ADAMTS (a Disintegrin And Metalloprotease 
with Thrombospondins 1 repeats) family of metalloproteases and was, therefore, designated 
ADAMTS13 (35). ADAMTS13 regulates the size of normally circulating VWF multimers by cleaving 
ultra-large multimers as soon as they are secreted from endothelial cells into plasma, thereby 
preventing their circulation in plasma and spontaneous platelet aggregation and thrombus formation 
(118).  
  
CHAPTER I - INTRODUCTION 
18 
 
3.2. Epidemiology, clinical manifestations, therapy and pathofisiology of TTP 
TTP is a rare life-threatening disorder with an estimated incidence of 2-10 cases per million per year 
(119). Demographic studies report a higher incidence in women (two-third of cases) and in african-
american people (nine-tenth of cases in the USA) (120). Mortality was very high (80%-90%), but has 
dramatically decreased to 10-20% after the introduction of plasma exchange, which is the treatment 
of choice of acute TTP episodes (121-124). In most cases TTP occurs as a single, acute episode, but 
there are chronic recurrent forms developed in up to 40% of patients, which usually have a genetic 
basis or are associated to the persistence of autoantibodies (118). 
TTP is characterized by the widespread formation in the microcirculation of platelet thrombi, 
associated with abundant intra-thrombus VWF. Microthrombi are found in several organs, mainly 
represented by brain, heart, kidney, lung and pancreas (118). TTP was originally described as a 
pentad of thrombocytopenia, microangiopathic haemolytic anemia, fluctuating neurological signs, 
renal impairment and fever (113). However, later on it was observed how neurologic signs, fever and 
impaired renal function were not consistently present in patients affected with this syndrome, 
especially in the early phase of the disease (122, 125). These observations lead to the currently 
accepted definition of TTP, whose diagnosis requires the association of microangiopathic haemolytic 
anaemia with fragmented erythrocytes and thrombocytopenia, with or without renal failure or 
neurologic abnormalities, and without alternative causes (122, 126, 127). Thrombocytopenia results 
from consumption of platelets in platelet-rich thrombi; haemolysis is the consequence of mechanical 
red blood cells fragmentation during flow through partially occluded high-shear small vessels. 
There are two different forms of TTP: congenital TTP, which is caused by mutations in the ADAMTS13 
gene (36), and acquired TTP, which is associated with the development of autoantibodies against 
ADAMTS13 (116). In the absence of ADAMTS13, ultra large VWF multimers secreted by activated 
endothelial cells are not cleaved properly and cause spontaneous platelet aggregates in conditions of 
high shear stress, leading to massive microvascular thrombosis and the above mentioned clinical 
manifestations characteristic of TTP (Figure 5). 
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Figure 5. Schematic representation of TTP pathogenesis. Multimeric VWF adheres to endothelial cells or to connective 
tissue exposed in the vessel wall. Platelets adhere to VWF through platelet membrane GPIb. In flowing blood, VWF in the 
platelet-rich thrombus is stretched and cleaved by ADAMTS13, limiting thrombus growth. In the absence of ADAMTS13, 
VWF-dependent platelet accumulation continues, eventually causing microvascular thrombosis and TTP. Adapted from 
(128). 
 
3.3. Congenital TTP 
Congenital TTP, also known as Upshaw-Schulman syndrome, is very rare (1 in 1 million) and 
represents 5% of all TTP cases (119). It is caused by homozygous or double heterozygous mutations 
in the ADAMTS13 gene, that affect protein secretion or function. Congenital TTP is inherited as an 
autosomal recessive condition and is often clinically manifested at birth or during childhood, even 
though cases where the disease became manifest in adulthood have been described (129, 130). Also 
the clinical course of the disease is very wide: some patients experience asymptomatic episodes of 
thrombocytopenia and anemia, while others develop multiorgan failure; some patients have multiple 
recurrent episodes and necessitate prophylactic plasma infusions, whereas others may only 
experience a single episode or remain disease-free lifelong (130-132). To date, more than 100 
mutations have been documented in patients with familial TTP (130, 133, 134). In a recent review of 
the literature, an analysis of the location of the mutations on the ADAMTS13 gene revealed no 
evident mutation hot spots (130).  
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Figure 6. Distribution of ADAMTS13 missense mutations on the protein. Red boxes indicate ADAMTS13 mutations 
expressed in vitro (130). 
 
However, 75% of the missense mutations are found in the N-terminal part of the molecule, up to the 
spacer domain (Figure 6). Most (60%) of the identified mutations are missense; the remaining 40% 
(nonsense, frameshift, splicing mutations) generates truncated forms of the protein. The majority of 
the mutations, among those analyzed by in vitro expression studies (about 20-30% of the reported 
gene mutations), cause reduced ADAMTS13 secretion (130). Lotta et al. showed that patients 
carrying the same ADAMTS13 gene mutations develop their first disease episode at a similar age, 
providing the first evidence of genotype-phenotype correlation in congenital TTP (130). In a 
subsequent study where ADAMTS13 activity was measured by surface-enhanced laser 
desorption/ionization time-of-flight mass spectrometry in 29 congenital TTP patients, Lotta and 
colleagues demonstrated that different ADAMTS13 gene mutations influence the severity of clinical 
phenotype by determining different levels of residual plasmatic activity of ADAMTS13 and that 
mutations affecting the N-terminal domains of the protein are associated with more severe clinical 
phenotype (134). 
Patients with congenital TTP usually respond well to plasma infusion. Despite that ADAMTS13 has a 
half-life of only 2-3 days (33), a periodic plasma infusion every 10-20 days is sufficient to supply 
enough ADAMTS13 to achieve normal platelet and haemoglobin level (127). Virally-inactivated 
intermediate purity factor VIII concentrate containing ADAMTS13 have also been used for the 
treatment of congenital TTP (135). Plasma-derived or recombinant concentrates of human 
ADAMTS13 are not yet available. However, a recombinant ADAMTS13 product for potential 
prophylaxis and treatment of TTP is currently under development (136-138). 
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3.4. Acquired TTP 
Two types of acquired TTP can be distinguished: idiopathic TTP and secondary TTP. Autoimmune 
idiopathic usually occurs in adults between 20 and 60 years old, in the absence of any obvious 
triggering event (139). Secondary TTP is associated with other physiological or pathological 
conditions, such as pregnancy, autoimmune diseases, infections, drugs, tumors, bone marrow 
transplantation, pancreatitis (140-146). These various conditions may directly injure endothelial cells 
with release of ultra-large VWF multimers in amounts exceeding the system ability to degrade them, 
despite the presence of normal or slightly reduced ADAMTS13 activity. In contrast to congenital TTP, 
the therapy of choice for acquired TTP consists of plasma exchange, required to remove the 
inhibiting autoantibodies, in association with immunosuppressive therapy (118). Steroids are used as 
immunosuppression to attain complete remission and, more recently, the use of rituximab, a 
monoclonal antibody directed against CD20 antigen on B cells, has also been proved highly 
efficacious in treating acquired TTP (118, 147). Recent therapeutical approaches aim at developing 
inhibitors of the binding between GPIb and ultra-large VWF multimers, preventing intravascular 
platelet aggregation in the microcirculation (148-150). Finally, a recombinant ADAMTS13 preparation 
has been shown to restore ADAMTS13 activity in plasma of TTP patients with ADAMTS13 inhibitors in 
vitro, suggesting a potential use of recombinant ADAMTS13 in the treatment of acquired TTP 
patients as well (151). 
Autoimmune TTP is caused by the severe deficiency of ADAMTS13 owing to autoantibodies that 
inhibit ADAMTS13 activity and/or bind the protease to accelerate its clearance from plasma through 
opsonization and/or yet unclear mechanisms (116, 152-154). Anti-ADAMTS13 antibodies were 
identified for the first time in 1998 in patients with acute acquired TTP (116, 117). Since then, 
autoantibodies inhibiting ADAMTS13 activity have been detected in most patients with acquired TTP 
(55, 116, 152, 153, 155-160) and much attention has been paid to the biochemical and functional 
characterization of these antibodies.  
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4. Anti-ADAMTS13 antibodies in acquired TTP 
 
4.1. Neutralizing activity of anti-ADAMTS13 autoantibodies 
In 1998, Tsai and Lian studied the activity of VWF-cleaving protease in plasma from patients with 
acquired TTP, patients with other autoimmune or blood disorders and in normal subjects. They found 
that all the samples obtained from patients during an acute episode of TTP had severe deficiency of 
the VWF-cleaving protease and that 67% of these presented inhibitory activity against the protease 
in mixing studies of heat-inactivated patient plasma and pooled normal plasma (116). They further 
characterized the source of the inhibitory activity and showed that it was due to antibodies, precisely 
to immunoglobulin (Ig) belonging to the G class. The same results were obtained by Furlan et al., who 
reported a case of a patient with recurrent episodes of TTP who was finally treated with splenectomy 
and corticosteroid treatment,  resulting in disappearance of the autoantibody and normalization of 
the protease activity and of the platelet count (117). In 2003, Scheiflinger and colleagues reported 
data on a patient with confirmed TTP who had severely reduced ADAMTS13 activity but surprisingly 
showed no ADAMTS13 inhibition in vitro (153). The authors developed an enzyme-linked 
immunosorbent assay (ELISA) using immobilized recombinant ADAMTS13 and they found high titers 
of IgM and IgG antibodies binding to ADAMTS13, without neutralizing its protease activity. Since 
then, anti-ADAMTS13 autoantibodies have been distinguished in two classes: neutralizing antibodies, 
or inhibitors, and non-neutralizing antibodies. If it is easy to assign particular antibodies to one type 
or another based on their functional activity in classical mixing studies, less straightforward is to 
explain the molecular mechanisms behind it (see section 4.3). Recent advances in our knowledge of 
the molecular interactions between ADAMTS13 and VWF and ADAMTS13 and anti-ADAMTS13 
antibodies are making increasingly clear how the latters may directly inhibit ADAMTS13 proteolytic 
activity. On the other hand, only speculations have been made on the mode of action of 
non-neutralizing antibodies. It has been suggested that they might enhance ADAMTS13 clearance 
from the circulation through opsonization and/or yet unclear mechanisms or that they could disturb 
the interaction of ADAMTS13 with physiologic binding partners, such as endothelial cells (73, 153). 
Another possible explanation is that non-neutralizing antibodies bind to regions of the protein that 
are not necessary for exerting protease activity under the conditions of in vitro assays. Finally, weak 
inhibitory antibodies might be missed because of the low sensitivity of the assays.  
Similarly to the quantification of anti-factor VIII inhibitors by Bethesda and Bethesda-modified assays 
(161, 162), anti-ADAMTS13 neutralizing autoantibodies can be titrated in vitro using mixing studies of 
heat-inactivated patient and pooled normal human plasmas at 1:1 dilution (116, 117). 
Immunoenzymatic assays like ELISA or Western Blot, using recombinant ADAMTS13, are used to 
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detect total anti-ADAMTS13 antibodies, regardless their neutralizing activity (153, 158). The clinical 
utility of these assays for the diagnosis, prognosis and the therapeutical management of TTP will be 
discussed later on in this dissertation (see section 5.2). 
 
4.2. Immunoglobulin classes and subclasses of anti-ADAMTS13 antibodies 
Anti-ADAMTS13 antibodies are usually immunoglobulin (Ig) G, although autoantibodies of IgA and 
IgM class have been described (152, 153, 159). In 2008, Dong et al. reported a fatal case of acquired 
TTP, in which the inhibitory activity of antibodies against ADAMTS13 rapidly escalated to extremely 
high levels despite daily plasma exchange and corticosteroid therapy (163). This increase was found 
to be because of a combination of higher antibody concentration and potency. Remarkably, the 
rising inhibitor level was associated with switching of the IgG subclasses, from IgG1 to IgG2 subclass, 
suggesting a Th1-type cytokine response and that an infection might have contributed to the 
exacerbation of TTP in this patient. 
Given the diverse biological function of the different IgG subclasses, the characterization of the 
subclass profile of anti-ADAMTS13 antibodies could provide insights into the pathophysiology of 
acquired TTP. An analysis of the IgG subclass distribution of anti-ADAMTS13 antibodies in 58 patients 
diagnosed with acute acquired TTP was reported by Ferrari and colleagues (164). IgG4 was found to 
be the most prevalent IgG subclass (90%), followed by IgG1 (52%), IgG2 (50%), and IgG3 (33%). IgG4 
was found either alone (33%) or with other IgG subclasses (67%), while it was not detected in 10% of 
the patients. The concurrent presence of several IgG subclasses indicate that the autoimmune 
response against ADAMTS13 is polyclonal and heterogeneous. Remarkably, absolute levels of IgG1 
and IgG4 were always inversely correlated (r2 = -0,927, P < 0,01) and patients with high IgG4 levels 
and undetectable IgG1 were found to be more prone to relapse than patients with low IgG4 levels 
and detectable IgG1. On the other hand, despite a higher number of patients is needed to reach 
statistical significance, the authors observed that patients were less likely to survive their first TTP 
event (four out of seven died) if they had IgG1 and very low or undetectable IgG4 levels, plus higher 
titres of other classes of anti-ADAMTS13 antibodies, particularly IgA. 
The distribution of Ig class and A/G subclasses was also studied in a more recent study by Pos et al. in 
48 acquired TTP patients (87). Anti-ADAMTS13 IgG was found in all samples tested, whereas anti-
ADAMTS13 IgM was found in 10% of the patients. Approximately 19% of plasma samples were 
positive for anti-ADAMTS13 IgA, precisely for anti-ADAMTS13 IgA1. IgG1 and IgG4 were present in 
73% and 69% of samples, respectively, whereas low levels of IgG2 and IgG3 were observed in 15% 
and 8%, respectively. Overall, these results confirmed the previous observation that IgG4 and IgG1 
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predominate in plasma of acquired TTP patients. No association analysis with disease state, episode 
severity or risk of relapse was performed. 
Further studies on a wider number of patients are needed to confirm these early data and establish a 
possible role of anti-ADAMTS13 antibodies classes and subclasses as prognostic biomarkers in 
acquired TTP. 
 
4.3. Epitope mapping and mode of action of anti-ADAMTS13 antibodies 
Epitope mapping studies showed that anti-ADAMTS13 antibodies are polyclonal, with a primary 
epitope in the spacer domain (55, 81, 83-87, 165) (Figure 7).  
 
 
 
 
Figure 7. Schematic protein domain structure of ADAMTS13 and localization of anti-ADAMTS13 autoantibody epitopes. 
The results of the main epitope-mapping studies are reported (see text for discussion) (A-D). Braces depict the ADAMTS13 
fragments used for epitope mapping of anti-ADAMTS13 Antibodies. Number of positive out of total cases are indicated. 
Row A: Klaus et al. investigated 25 patients using E coli–derived recombinant (r) ADAMTS13 fragments (55). Row B: Luken 
et al. performed epitope mapping in 7 patients using full-length ADAMTS13 and ADAMTS13 fragments produced in insect 
cells (83). Row C: Zheng et al. performed epitope mapping on 67 patient samples using rADAMTS13 and rADAMTS13 
fragments produced in mammalian cell lines (86). Row D: Pos et al. analyzed 48 patients using wild-type and mutant 
rADAMTS13 fragments produced in mammalian cells (87). 
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In the first study by Klaus and co-workers, a series of ADAMTS13 domains were expressed in 
Escherichia coli and the reactivity of purified recombinant fragments with anti-ADAMTS13 
autoantibodies from 25 patients with severe ADAMTS13 deficiency and neutralizing anti-ADAMTS13 
antibodies was evaluated by Western Blot analysis (55). All TTP plasmas contained antibodies 
directed against the cysteine-rich and spacer domains of ADAMTS13. Remarkably, the plasma of 3 
patients reacted exclusively with these domains. In 64%, 28% and 56% of the plasmas, antibodies 
recognizing the CUB domains, the TSP2-8 variant and the fragment consisting of the 
metalloprotease/disintegrin-like/TSP1 domains were detected, respectively. Unexpectedly, 
antibodies reacting with the propeptide region were present in 20% of the plasmas, confirming that 
its cleavage is not required for proper folding and secretion of ADAMTS13.  
A second study by Luken et al. analyzed the epitope mapping profile of 7 TTP patients with 
ADAMTS13 activity below 5%, using recombinant ADAMTS13 fragment expressed in insect cells and 
immunoprecipitation plus Western Blot analysis (83). All samples tested were found to react towards 
a fragment consisting of the disintegrin-like/cysteine-rich/spacer domains and towards the isolated 
spacer domain. No binding to propeptide, metalloprotease and CUB domains was detected, whereas 
one patient plasma reacted to the TSP2-8 domains. Despite discrepancies that could be due to the 
different number of samples analyzed or to differences in the experimental approaches, the results 
of this study confirmed the previous one, inasmuch as the spacer domain was identified to harbor a 
major epitope for anti-ADAMTS13 antibodies in acquired TTP. 
The studies by Klaus and Luken have limitations since they employed non-physiological antigens or 
detection methods or involved a small case series of patients. To circumvent the potential pitfalls of 
the first two epitope mapping studies, Zheng and colleagues used recombinant ADAMTS13 variants 
expressed in human embryonic kidney (HEK)-293 cells and immunoprecipitation plus Western 
Blotting to detect anti-ADAMTS13 antibodies in a large cohort of acquired TTP patients (86). 
Sixty-seven patients with acute acquired autoimmune TTP and  severe deficiency of ADAMTS13 in 
88% of the cases were included in the study. Anti-ADAMTS13 IgG from all patients bound full-length 
ADAMTS13 and a variant deleted of the CUB domains. Approximately 97% (65/67) of patients 
harbored antibodies targeted against a variant truncated after the spacer domain. However, only 
12% of patient samples reacted with a variant lacking the Cys-rich and spacer domains, confirming 
these domains as the most targeted by anti-ADAMTS13 antibodies. In addition, approximately 37%, 
31%, and 46% of patient IgG interacted with the ADAMTS13 fragment containing TSP2-8 repeats (T2-
8), CUB domains, and TSP5-8 repeats plus CUB domains, respectively. Importantly, Zheng et al. 
investigated for the first time whether there was an association between the positive or negative 
recognition of the C-terminal domains (TSP2-8 and/or CUB domains) by anti-ADAMTS13 antibodies 
and clinical and laboratory markers of acute episode severity, such as neurological symptoms, lactate 
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dehydrogenase (LDH) and creatinine levels and platelet count. If no correlation was found with the 
frequence of neurological symptoms, LDH and creatinine levels, the presence of IgG targeted against 
the T2-8 and/or CUB domains was inversely correlated with platelet count on admission. 
The reactivity of anti-ADAMTS13 antibodies against the C-terminal domains of ADAMTS13 was also 
recently investigated by Pos et al. in 48 acquired TTP patients with severe ADAMTS13 deficiency and 
high inhibitor titre (87). Anti-TSP2-8 antibodies were found in 17% of the samples, whereas anti-CUB 
antibodies were detected in 35% of patients analyzed, percentage that is similar to the value of 31% 
observed by Zheng and co-workers.  
A different experimental approach was used by Yamaguchi and co-workers to examine the epitope 
recognized by anti-ADAMTS13 antibodies (165). In this study, purified IgG from 13 acquired TTP 
patients was screened by a phage display library expressing approximately 30 to 50 amino acids of 
the ADAMTS13 peptide sequence. Different peptide sequences were obtained from almost all of the 
ADAMTS13 domains, in particular an identical amino acid sequence in the C-terminus of the spacer 
domain from Gly662 to Val687 was recognized by autoantibodies from 5 TTP patients. 
Given the striking evidences supporting the primary role of the spacer domain in the interaction 
between anti-ADAMTS13 antibodies and the metalloprotease, several studies have been performed 
to define the recognized epitopes in this domain at the amino acidic level. A first study employing a 
panel of ADAMTS13-ADAMTS1 hybrids identified residues 572-579 and 657-666 as crucial for binding 
of anti-ADAMTS13 antibodies (85). A subsequent study fine-tuned the details of the interaction, 
showing that replacement of Arg660, Tyr661 and Tyr665 with alanine in the spacer domain of 
ADAMTS13 reduced or abolished the binding of two human monoclonal antibodies previously 
isolated (84) and polyclonal antibodies from plasma of 6 patients with acquired TTP (81). Moreover, 
surface plasmon resonance analysis of the binding between this mutant ADAMTS13 and short VWF 
peptides demonstrated that residues Arg660, Tyr661 and Tyr665 identify a binding site for the A2 
domain of VWF, explaining why antibodies against this region may interfere with 
ADAMTS13-mediated VWF proteolysis (81). In a further study by the same researchers, Arg568 and 
Phe592 were also found to contribute to the antigenic surface in the spacer domain of ADAMTS13, as 
90% of the acquired TTP patients tested (43 out of 48) lost reactivity towards the spacer domain 
following introduction of multiple alanine substitutions of these residues, in addition to Arg 660, 
Tyr661 and Tyr665 (87).  
All together, the results from epitope mapping studies using recombinant ADAMTS13 truncated 
variants demonstrate that the immune response against ADAMTS13 is polyclonal and engages 
multiple domains of the metalloprotease. Anti-ADAMTS13 antibodies recognizing a primary epitope 
on the Cys-rich/spacer domains are present in 97%-100% of patients with acquired TTP, and up to 
64% of these patients also have antibodies against other ADAMTS13 domains. In particular, 
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fine-mapping studies have shown that exosite-3 (i.e. Tyr659-Tyr665) and several other adjacent 
aminoacid residues (i.e. Arg568 and Phe592) in the spacer domain constitute a major antigenic 
epitope for anti-ADAMTS13 autoantibodies in idiopathic TTP. As yet, the epitopes of ADAMTS13 
antibodies binding to other domains have not been identified. 
Deletion, mutagenesis and structural studies aimed at discovering the molecular mechanisms that 
regulate VWF binding and cleavage by ADAMTS13 identified several crucial exosites spanning the 
whole molecule of ADAMTS13 (see sections 2.2, 2.3). Besides the above mentioned exosites-3 in the 
spacer domain, subsites adjacent to the active site of the enzyme and exosites involved in 
ADAMTS13-mediated proteolysis of VWF were indeed found in the disintegrin-like and Cys-rich 
domains at the N-terminal half of the metalloprotease (REF). Recently, it has been shown that 
infusion of an inhibitory murine monoclonal antibody directed towards the metalloprotease domain 
of ADAMTS13 results in severe thrombocytopenia and microangiopathic haemolytic anemia in 
baboons (166). On the other hand, ADAMTS13 C-terminal domains were showed to play a role in the 
recognition and proteolytic cleavage of native VWF under fluid shear stress (77, 92). Moreover, the 
distal TSP1 repeats bind the endothelial cell surface, which may enhance proteolytic cleavage of 
newly released UL-VWF on endothelial cells by ADAMTS13 under flow conditions (73). Thus, 
antibodies against the C-terminal domains of ADAMTS13 might cause ADAMTS13 deficiency by 
directly inhibiting its interaction with VWF in vivo or by interfering with ADAMTS13 binding to the 
endothelial surface. Furthermore, the inverse correlation between anti-ADAMTS13 IgG positivity for 
the middle and distal C-terminal domains of ADAMTS13 and the patients’ initial platelet counts 
observed by Zheng et al. further supports the hypothesis that anti-ADAMTS13 autoantibodies against 
the more distal C-terminal domains in conjunction with those against the proximal C-terminal 
domains may have a synergistic effect on ADAMTS13 function in vivo (86). 
 
4.4. Molecular characterization of anti-ADAMTS13 antibodies genes and etiology of 
autoimmune TTP 
Antigen driven selection governs the production of antibodies; a limited number of gene segment 
rearrangements generates a large repertoire of antibodies with virtually unlimited specificities. The 
molecular characterization of human monoclonal anti-ADAMTS13 antibodies isolated using 
immunoglobulin (Ig) V-gene phage-display libraries derived from acquired TTP patients, showed that 
antibodies directed towards ADAMTS13 preferentially incorporate heavy chain gene segment VH1-69 
(84, 167, 168). The heavy chain complementarity determining region (CDR) 2 of the VH1-69 germline 
contains a unique hydrophobic 5 amino acid-long motif which may interact with hydrophobic 
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residues Tyr661 and Tyr665 on the antigenic surface of ADAMTS13 spacer domain. Based on this 
observation, it was hypothesized that shape complementarity between VH1-69 encoded peptide 
sequence and ADAMTS13 spacer domain explained the frequent usage of this Ig gene segment in 
anti-ADAMTS13 antibodies (169). 
The etiology of autoimmune TTP is unknown. Interestingly, a case report described the development 
of anti-ADAMTS13 antibodies in two identical twins, suggesting that a genetic predisposition can be 
present even in the acquired form of the disease (170). Moreover, the presence of HLA-DRB1*11 was 
recently identified as a risk factor for acquired TTP, while HLA-DRB1*04 was underrepresented in this 
patients compared with controls and might have a protective role (171, 172). This observation 
suggests that ADAMTS13-derived peptides might be presented on HLA-DRB1*11 on the surface of 
antigen presenting cells promoting the activation of ADAMTS13-specific CD4+ T cells. Sorvillo et al. 
recently demonstrated that recombinant ADAMTS13 is efficiently internalized by human immature 
monocyte-derived dendritic cells in a mannose receptor dependent manner. Furthermore, very 
recently, the same researchers have shown that pulsing of dendritic cells of HLA-DRB1*11 positive 
donors with 100 nM ADAMTS13 resulted in presentation of a single CUB2 derived ADAMTS13 
peptide, suggesting that presentation of this CUB2 domain derived peptide on DRB1*11 may provoke 
proliferation of low affinity self-reactive CD4+ T cells that have escaped negative selection in the 
thymus and contribute to the onset of acquired TTP (173). Besides the immune dysregulation of the 
HLA system, additional support for a role of T cells in the pathogenesis of acquired TTP derives from 
the clinical observation that exacerbation of acute TTP episodes was less frequent in patients who 
received cyclosporine A, a T cell immunosuppressant, in addition to plasma exchange therapy (174). 
Moreover, isotype switching of antibodies, which is a common feature of acquired TTP, is dependent 
on the presence of antigen specific CD4+ T cells. 
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5. ADAMTS13-related laboratory measurements and their clinical utility 
Since the discovery of the VWF-cleaving protease, several assays have been developed to quantify 
ADAMTS13 and anti-ADAMTS13 antibodies in human plasma. Such tests includes assays of 
ADAMTS13 antigen, ADAMTS13 activity and neutralizing or non-neutralizing anti-ADAMTS13 
antibodies. 
 
5.1. ADAMTS13 antigen assays 
Several immunoassays, in-house developed or commercial kits, are available for the quantification of 
ADAMTS13 antigen level (158, 175-177). The most commonly used assays are represented by 
Enzyme-Linked Immunosorbent Assays (ELISA), in which plasma ADAMTS13 is “sandwiched” 
between specific monoclonal or polyclonal antibodies. ADAMTS13 antigen determination can help 
the diagnosis of congenital TTP after the presence of anti-ADAMTS13 antibodies has been excluded. 
In acquired TTP, despite low ADAMTS13 activity, antigen levels may be normal (due to the fact that 
antigen assays may not distinguish between free ADAMTS13 and immune complexed ADAMTS13) or 
reduced following increased clearance from the circulation. Therefore, ADAMTS13 antigen 
measurement is not usually helpful in the management of acquired TTP. However, recently, a severe 
deficiency of ADAMTS13 antigen level in the acute phase of the disease, was found to be associated 
with unfavorable short-term outcomes, such as death and disease exacerbation (178).  
 
5.2. ADAMTS13 activity assays 
ADAMTS13 activity assays are based on the cleavage of VWF (full-lenght VWF or synthetic VWF 
peptides comprising the scissile bond) by ADAMTS13 in patient plasma, followed by the direct or 
indirect detection of the VWF cleavage products (179). The assays based on full-lenght VWF are 
sensitive (3%-6% of the reference standard ADAMTS13 activity) and reproducible, but cumbersome, 
time-consuming (2-3 days) and performed in non-physiological conditions, using denaturing agents. 
On the other hand, the assays based on VWF peptides are very sensitive (1%-3% of the reference 
standard ADAMTS13 activity), reproducible, easy and rapid (1–4 h), performed in the absence of 
denaturing agents, but they use non-physiologic VWF substrates (179). Several studies have been 
performed to compare and validate ADAMTS13 assays (180-185). In the frame of an international 
multicentre study, eight functional assays were compared by testing six different test plasmas 
ranging from 100% to 0%, prepared centrally by dilutions of one ADAMTS13 congenital deficient 
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plasma (arbitrarily set at 0%) into one normal pooled plasma (100%) (184). Comparative analysis 
showed that functional assays employing modified VWF peptides as substrate for ADAMTS13 offer 
the best performance characteristics. 
Direct assays are based on the detection of cleavage products of a given substrate, whether it is a 
full-lenght VWF, a VWF A2 domain or short VWF peptides, whereas indirect assays depend on 
measuring the residual substrate or its disappearance. Agarose or polyacrylamide gel electrophoresis 
(PAGE), Western blotting and fluorescence resonance energy transfer (FRET) technique are the most 
commonly used methods for direct detection of cleavage substrate, whereas ELISA (that includes the 
collagen-binding assay) and platelet aggregation techniques are the most widely used techniques to 
detect residual VWF. 
5.2.1. SDS-Agarose gel electrophoresis and Western Blotting 
This assay was initially developed by Furlan et al. (18, 115) to measure ADAMTS13 activity in plasma. 
Purified VWF is incubated with citrated plasma samples for approximately 24 hours in the presence 
of urea and BaCl2, then agarose gel electrophoresis and Western blotting with peroxidase-conjugated 
anti-VWF antibody are used to determine the proteolytic degradation of purified VWF multimers. 
The relative amount of ADAMTS13 activity is expressed as percentage of serially diluted normal 
human plasma. This assay permitted the identification and characterization of ADAMTS13 and it is 
currently used to evaluate plasma or recombinant ADAMTS13 activity in research studies. However 
this assay is very complex and requires technical expertise in handling agarose gel electrophoresis, 
transfer and Western blotting, therefore it cannot be used in clinical practice. 
5.2.2. SDS-PAGE and Western Blotting 
Tsai et al. (13, 116) initially developed this assay based on detection of dimeric VWF fragments of 176 
and 140 kd on denatured, but unreduced SDS-PAGE and Western blotting. Alternatively, the same 
biochemical techniques may be applied using epitope-tagged VWF fragments (His-A2 domain or 
GST-VWF73) as substrate (53, 67, 186), whose cleavage is detected with an anti-His (186) or anti-GST 
(53, 67) antibody. The cleavage of a small recombinant domain or a peptidyl substrate does not 
require denaturing reagents. 
5.2.3. FRET assay 
Förster (or Fluorescence) resonance energy transfer (FRET) is a physical phenomenon that relies on 
the distance-dependent transfer of energy between two dyes or fluorophore, named donor and 
acceptor. If the donor emission spectrum and the acceptor absorbance spectrum overlap, the energy 
that is initially absorbed by the donor molecule is subsequently transferred to the acceptor molecule. 
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Due to its high sensitivity to distance, FRET has been used to investigate molecular interactions or, as 
in this case, proteolytic reactions. FRETS-VWF73 is a chemically synthesized, fluorogenic peptide, 
containing the 73-amino acids from Asp1596 to Arg1668 of VWF, the region of VWF A2 domain that 
provides the minimal substrate for ADAMTS13 (53, 187). Within this peptide, the Gln1599 residue at 
the P71 position is converted to a 2,3-diaminopropionic residue (A2pr) modified with a 2-(N 
methylamino)benzoyl group (Nma). The N1610 residue of the P5’1 position is converted to A2pr 
modified with a 2,4-dinitrophenyl group (Dnp) (Figure 8). When the Nma group, the acceptor 
fluorophore, is excited at 340 nm, fluorescence resonance energy is transferred to the neighboring 
donor fluorophore, Dnp. If the bond between Tyr1605 and Met1606 is cleaved, the energy transfer 
quenching the fluorescence does not occur, allowing the emission of fluorescence at 440 nm from 
Nma. Proteolysis of FRETS-VWF73 by ADAMTS13 can be followed in real-time as an increase of 
fluorescence over time within a 1-h period, using a 96-well format in commercial plate readers with 
340/450 nm filters (187).  
 
 
 
Figure 8. Structure of FRETS-VWF73. Within the 73-amino-acid peptide sequence, corresponding to the region from D1596 
to R1668 of VWF, Q1599 and N1610 were substituted with A2pr(Nma) and A2pr(Dnp) respectively. The arrowhead 
indicates the site cleaved by ADAMTS13. Adapted from (187). 
 
As in other ADAMTS13 activity assays, the assay buffer contains divalent metal ions to activate 
ADAMTS13 (25 mM CaCl2 being the optimal ion concentration), and no chloride ions, as higher NaCl 
concentrations inhibit cleavage (18). FRETS-VWF73 assay is performed at a pH of 6, differing from 
previous studies reporting an optimal pH of 8-10 for the cleavage reaction (18). Finally, as in other 
assays involving short VWF peptides as substrate, denaturating agents are not required. Compared 
with the collagen binding assay (described below), the FRET-VWF73 assay has several advantages: it 
is more sensitive (limit of detection (LOD) = 3% VS 6%), it is easier and shorter to perform (1 h VS 20 
h of substrate digestion) and does not require the use of denaturating agents to expose VWF A2 
domain. On the other hand, it does not employ a physiological multimeric VWF substrate. Moreover, 
                                                          
1
 In an proteolysis reaction, residues are commonly indicated by the string “P/Snumber”. The letter “P” or “S” 
indicate the substrate or the enzyme, respectively, whereas the number indicates the position of the residue 
from the scissile bond; the prime indicates residues C-terminal to the scissile bond. 
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plasma proteins, hemoglobin and bilirubin may interfere with FRETS-VWF73 assay because of their 
spectral properties at 340/450 nm. For example, bilirubin in hyperbilirubinemic patients’ plasma (at 
concentrations higher than 100 uM) interferes with fluorescence evolution in this assay by acting as a 
quencher at the emission wavelength of 450 nm, potentially leading to a misdiagnosis of a severe 
deficiency of the enzyme (188). Modifications of the assay to avoid plasma autofluorescence have 
been recently proposed, using fluorophores that absorb/emit at higher wavelengths (189) or in the 
near infrared (190). 
5.2.4. Surface Enhanced Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry 
(SELDI-TOF-MS) 
An ADAMTS13 activity assay based on the detection of VWF cleaved fragments by mass 
spectrometry has been developed by Jin and colleagues (191, 192). This type of assay is not 
commonly used, nor applicable for routine laboratory practice because of the technology used, but it 
is worth-describing due to its extremely high sensitivity, being able to detect ADAMTS13 activity 
levels as low as 0,5% (192). A recombinant VWF73 peptide containing a His6 tag at the C-terminus is 
incubated with plasma samples for 16 hours. The cleavage products are bound to a Nickel-coated 
chip through their His6 tag and quantified using SELDI-TOF-MS. This assay was recently used to 
determine ADAMTS13 activity values in congenital TTP patients with undetectable activity by 
commonly used assays, permitting to establish a genotype-phenotype correlation based on residual 
ADAMTS13 activity levels (134).  
5.2.5. Collagen-Binding Assay (CBA) 
Initially described by Gerritsen et al. (193) and modified by many others (194-197), the CBA assay for 
the measurement of ADAMTS13 activity derives from an enzyme-immunoassay for measuring the 
collagen-binding activity of human VWF in plasma (198, 199) and is based on preferential binding of 
large VWF multimers to type III human collagen. Purified VWF or ADAMTS13-depleted plasma is 
incubated with patient plasma or normal human plasma (as control) in the presence of 5 mM Tris-HCl 
(pH 8.0), 1,5 M urea, and 3 mM BaCl2 for 2-24 hours at 37 or 25 °C. The proteolytic degradation leads 
to low molecular weight forms of VWF, which show impaired binding to microtitre plates coated with 
human collagen type III. Bound VWF is quantified by peroxidase-conjugated anti-VWF antibodies, 
followed by a chromogenic reaction and absorbance measurement (193). Among assays using full-
length VWF as substrate, this assay is relatively simple to perform and can accommodate many 
samples simultaneously. 
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5.2.6. Ristocetin-induced aggregation 
After digestion of the purified VWF in the buffer (similar to that in collagen-binding assay), the 
residual VWF is determined by a ristocetin cofactor activity (RiCof) in a platelet aggregometer (200, 
201). 
5.2.7. Enzyme-Linked Immunosorbent Assay (ELISA) 
This assay uses N- and C-terminal tagged recombinant fragment (VWF A2 domain or VWF73) as a 
substrate (202, 203). The substrate is immobilized to a microtitre plate with an antibody to one tag. 
After incubation of the immobilized substrate with plasma samples, an antibody to another tag 
detects the residual substrate. The proteolytic activity of ADAMTS13 is inversely proportional to the 
residual substrate concentration. In a variation of this method, a single N-terminal GST-tagged 
VWF73 is captured on a microtitre plate and incubated with plasma sample (204). The cleaved 
product is directly detected by a monoclonal antibody specific for the Tyr1605 residue of VWF73 
scissile bond. 
5.2.8. Flow-based assays 
Three types of assays using flow conditions for measuring ADAMTS13 activity have been described 
(11, 205, 206). First, Shenkman et al. used a cone and plate(let) analyzer to evaluate the ability of TTP 
plasma to increase deposition on a polystyrene surface from normal plasma at a shear rate of 1800 s-
1 (205). Second, Dong et al. described that ULVWF multimers, upon release from cultured endothelial 
cells, form extremely long, platelet-decorated string-like structures on the surface of endothelial cells 
under fluid shear stress (11). When perfused with normal human plasma, the string-like structures 
disappear rapidly, and proportionally to plasma concentration (207), within a few minutes, indicating 
the cleavage of ULVWF by ADAMTS13. On the contrary, ULVWF strings persist when plasma from TTP 
patients with severe ADAMTS13 deficiency is perfused (11). Under flow conditions, cleaving ULVWF 
occurs at 1000-fold faster kinetics than that observed under static conditions. This assay is performed 
in more physiological conditions compared with the other described assays: it uses a physiological 
substrate, the interaction between ADAMTS13 and VWF is regulated by shear stress and the 
environment is represented by endothelial cells on a collagen-coated slide. However, the evaluation 
of this assay in a multicentre study showed that it may only be reliable in discriminating ADAMTS13 
levels higher or lower than 20%, without measuring a precise value of ADAMTS13 activity (184). 
Moreover, this assay is cumbersome and depend on endothelial cells culturing, thus it is not suitable 
for routine laboratory tests. Recently, a third assay performed at high shear conditions has been 
described by Han and colleagues (206). A mixture of purified VWF and patient plasma is subjected to 
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vortexing for 60 minutes at the rotation rate of 2,500 rpm, which generates a shear-stress 
corresponding to that found in the arteries. The cleavage products are then detected by Western 
blotting following a separation on an agarose SDS-gel. This assay showed a good agreement with a 
FRET-based assay in detecting ADAMTS13 activity and inhibitors, however its sensitivity and 
specificity for the diagnosis of TTP remain to be established (206). 
In all the reported activity assays, a number of variables may interfere with assay results. First, all the 
validated assays measure ADAMTS13 activity in static conditions which do not reflect the in vivo 
physiologic flow conditions. Furthermore, the assays based on full-length VWF, in order to unfold 
VWF A2 domain, use denaturing agents as urea or guanidine-HCl, that could also affect the enzymatic 
activity of ADAMTS13 and/or antibody-ADAMTS13 interactions, artifactually changing the assay 
results. The use of short VWF peptides does not require denaturing agents, but the lack of VWF 
domains (as the C-terminal domains), that have been found to be important for VWF recognition by 
ADAMTS13 (see sections 2.2, 2.3) may alter the proteolytic cleavage of VWF in a way that does not 
reflect the in vivo situation. For example, anti-ADAMTS13 antibodies against the C-terminal domains 
of ADAMTS13, which have been shown to interact with VWF D4-CK domains, may lose their effect in 
such assays. All these reported factors could influence the clinical utility of each assay. 
5.2.9. Discrepancies in ADAMTS13 activity levels between CBA and FRET assays 
CBA and FRET assay are two of the most widely used methods for the measurement of ADAMTS13 
activity in thrombotic microangiopathies. As described above (see section 5.2), CBA and FRET assay 
differ for the substrate used (full-length VWF VS VWF73 peptide), for the use of denaturing agents 
(urea VS none) and for the detection method (indirect detection of cleavage products through 
absorbance measurement VS direct detection of cleavage products through fluorescence 
measurement). Several studies have been perform to evaluate the performance and clinical utility of 
ADAMTS13 activity assays based on full-length or VWF peptides, most of them on a small number of 
patients (154, 182, 183, 185, 208). In a recent study by Palla et al., a large number of plasma samples 
(400) obtained from patients affected with different thrombotic microangiopathies were analyzed to 
investigate whether or not there was a concordance between CBA and FRET assays (185). An 
excellent correlation between the two assays (Spearman’s rho = 0.90, p = 1x10–5) was observed in all 
samples tested. After categorizing the samples into subgroups based on ADAMTS13 activity level 
(Table 1), agreement was found in 72% of the cases. A particularly good agreement (90%) was found 
in samples with ADAMTS13 activity lower than the detection limit of the assay. However, in some 
samples, the results of the two assays were considerably discordant (Table 1), ADAMTS13 activity 
measured by FRET being consistently lower than that measured by CBA. Most importantly in 2,5% 
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(n=10) of the samples ADAMTS13 activity was higher than 10% by CBA, but undetectable by FRET. On 
the whole, a considerable discrepancy between normal ADAMTS13 by CBA and undetectable levels 
by FRET was observed in 1% (n=4) of samples, all obtained from patients with TTP.  
 
 
 
Table 1. Cross-tabulation of the distribution of ADAMTS13 activity results by CBA and FRET assays after arbitrary 
categorization into five subgroups according to the plasma levels of ADAMTS13 activity: i) less than the detection limit, ii) 
from the detection limit to 10% (the plasma level previously adopted by us and others to define severely reduced activity), 
iii) from 11–20% (moderate deficiency), iv) from 21% to the lower limit of the normal range (mild deficiency), and v) the 
normal range of the assays. Adapted from (185). 
 
Modifications of FRET assay experimental conditions, such as pH buffer (pH 8 instead of 6) and 
prolongation of the digestion time (4 hours instead of 1 hour) were tested, but none of these 
variations affected the degree of discrepancy. A chromogenic activity-ELISA (Technoclone), which 
employs the VWF73aa peptide as FRET, and the chromogenic detection method as CBA, was 
performed on 97 samples, including all the discordant ones. This assay confirmed the FRET assay, 
indicating that the observed discrepancy was not related to the detection method. Finally, Palla and 
colleagues analyzed those conditions/features that might interfere with ADAMTS13 measurement, 
such as the type of the disease (TTP VS no TTP), the state of the disease (acute or remission), the 
type of treatment at the time of blood sampling (plasma treatment, corticosteroids or antiplatelet 
agents), hyperbilirubinaemia (188), high levels of endogenous VWF antigen and the presence of anti-
ADAMTS13 antibodies. None of these conditions seems to explain the obtained discrepancy, except 
for the presence of anti-ADAMTS13 antibodies which was more frequent in discordant samples than 
in concordant samples (p<0.01) (185).  
Discrepancies between full-length VWF- and VWF peptide-based assays in measuring ADAMTS13 
activity in samples from TTP patients were also found in other studies (154, 160, 209). So far, the 
cause of these discrepancies are unknown. The clinical helpfulness of ADAMTS13 activity testing in 
the diagnosis and prognosis of TTP, in particular as a prognostic marker for relapse, is 
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well-established. Thus, understanding the reason of these discrepancies might avoid a potential 
misdiagnosis or wrong management during follow-up of this rare, but life-threatening disease. 
5.2.10. Clinical utility of ADAMTS13 activity assays 
A severe deficiency of ADAMTS13, define as an ADAMTS13 activity level below 10%, strongly suggest 
a diagnosis of TTP, although it has been reported in 13% of atypical haemolytic uremic syndrome 
(HUS) cases (210) and in 16% of disseminated intravascular coagulation (DIC) (104). After the first 
retrospective studies (13, 18), who found a severe ADAMTS13 deficiency in 87%-100% of idiopathic 
TTP patients, subsequent investigations challenged the implications of the original findings, as severe 
ADAMTS13 deficiency was variably found in 18% to 72% of patients clinically diagnosed with TTP 
(157, 194, 211-216). The variability of the results might be due to differences in the criteria used to 
select the cohort of patients. Idiopathic TTP patients are well identified by severe ADAMTS13 
deficiency, whereas secondary TTP cases, such as those associated with tumors, bone marrow 
transplantation or HIV infection, are more frequently associated with normal or moderately reduced 
ADAMTS13 activity (157). 
A critical issue for the management of TTP patients is whether or not ADAMTS13-related assays may 
be prognostic biomarkers of short-term outcomes in the acute phase of the disease. Results from 
two prospective studies showed that patients with ADAMTS13 activity below 10% had more 
favorable short-terms outcomes, in terms of better response to plasma therapy and low mortality 
rate (157, 194). In a more recent prospective study by Kremer-Hovinga et al., survival was not 
statistically different between patients with ADAMTS13 activity level below and above 10% (p=0.11), 
however it was higher in the first group of patients (160). These results may reflect the severity of 
the associated diseases or conditions that are usually found in TTP patients with detectable levels of 
the metalloprotease (157, 217). 
Since up to 40% of TTP patients develops a recurrent form of the disease, a second major aspect of 
ADAMTS13 testing is represented by its potential utility as predictor of relapse. Peyvandi et al. 
reported that survivors of an acute TTP episode with severely reduced ADAMTS13 activity in 
remission had an approximately threefold greater likelihood of relapsing (158). The association 
between severe ADAMTS13 activity during remission and higher risk of recurrence was found also by 
Ferrari et al. (159) and Jin et al. (192). Kremer-Hovinga and colleagues recently reported a higher 
relapse rate among patients with ADAMTS13 activity level below 10% than among those with 
ADAMTS13 activity level above 10% (160). On the whole, several prospective and retrospective 
studies had clearly established that a severe deficiency of ADAMTS13 activity is associated with a 
higher risk of relapse both in the acute (157, 160, 194) and in the remission phase (158, 159, 192).  
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5.3. Anti-ADAMTS13 antibodies assays 
Anti-ADAMTS13 autoantibodies have been distinguished in two classes: neutralizing antibodies, or 
inhibitors, and non-neutralizing antibodies, depending on whether or not the antibodies block 
proteolytic cleavage of VWF in an in vitro assay. Similarly to the quantification of anti-factor VIII 
inhibitors by Bethesda and Bethesda-modified assays (161, 162), anti-ADAMTS13 neutralizing 
autoantibodies can be titrated in vitro using mixing studies of heat-inactivated patient and pooled 
normal human plasma at a 1:1 or several dilutions (116, 117). Residual ADAMTS13 activity is then 
measured by one of the functional assay described above. Inhibitor assays are far from being 
optimized and generally lack sensitivity. Different functional assay to determine residual ADAMTS13 
activity and different experimental conditions, in terms of ratios of patient plasma and pooled 
normal human plasmas, incubation time and incubation temperatures (160, 194, 201, 208, 218) have 
been employed to measure ADAMTS13 inhibitors. A comparison between the assays used has never 
been performed. 
Immunoenzymatic assays like ELISA or Western Blot are used to detect total anti-ADAMTS13 
antibodies, regardless their neutralizing activity (153, 158). This methods are based on the binding of 
anti-ADAMTS13 antibodies to recombinant ADAMTS13, either captured on an ELISA plate or 
subjected to SDS-PAGE and Western blot, followed by detection by enzyme-linked anti-human 
immunoglobulin antibodies. Western Blot method seems to be more sensitive than ELISA, although is 
not a quantitative assay and may miss conformational antibodies. On the other hand, ELISA methods 
may vary in relation to the dilution of plasma used, the ADAMTS13 antigen captured on the plate and 
the coating antibody. 
The results of studies assessing the clinical utility of the measurement of ADAMTS13 inhibitor titre 
provide conflicting results. Most studies (159, 194, 219, 220) reported poorer responses to plasma 
exchange and higher mortality rates in patients with high inhibitor titres, whereas others (157, 159) 
did not. Recently, a neutralizing autoantibody titre of 2 or more Bethesda units per ml was found to 
be associated with lower survival among patients with severe ADAMTS13 deficiency (160). In a 
prospective cohort study, Ferrari et al. investigated 32 patients who had low plasma levels of 
ADAMTS13 activity at the time of the first acute episode and subsequently achieved remission. In 
them, the presence of high levels of anti-ADAMTS13 inhibitors at presentation was associated with 
the persistence of undetectable ADAMTS13 activity, which was in turn predictive of relapses within 
18 months (159). In a study by Peyvandi et al., the presence of anti-ADAMTS13 antibodies during 
remission was predictive of recurrent disease, whereas Jin et al. found no predictive value for anti-
ADAMTS13 IgG levels (192). Overall, it appears that the presence of anti-ADAMTS13 antibodies at 
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high titres during acute TTP or during remission are associated with a worse prognosis and with a 
higher risk of relapse, although larger prospective studies are needed to confirm these findings (217).  
 CHAPTER II – AIMS 
 
Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening microangiopathic disorder, 
characterized by thrombocytopenia, hemolytic anemia and signs and symptoms of ischemic organ 
dysfunctions due to the persistence of highly thrombogenic ultra large (UL) von Willebrand factor 
(VWF) multimers in the microcirculation. TTP is associated with the severe deficiency of ADAMTS13, 
the metalloprotease responsible for the proteolytic regulation of VWF multimers size. In the acquired 
form of the disease, the severe deficiency of ADAMTS13 is caused by anti-ADAMTS13 antibodies that 
inhibit ADAMTS13 activity (neutralizing anti-ADAMTS13 antibodies or inhibitors) and/or increase its 
clearance from the circulation through yet unknown mechanisms (non-neutralizing anti-ADAMTS13 
antibodies). 
Since the role of ADAMTS13 in the pathogenesis of TTP has been discovered, many different assays 
have been developed to measure ADAMTS13 and anti-ADAMTS13 antibodies. These assays have 
been compared in the frame of international multicenter studies and further standardization is 
necessary. Moreover, the studies performed to assess the utility of ADAMTS13 measurements in 
clinical practice provided conflicting results.  
With this background, the present research has two main objectives: to evaluate, in our cohort of 
acquired TTP patients, the clinical utility of ADAMTS13-related biomarkers and to investigate which 
ADAMTS13 assay may be more reliable in the management of acquired TTP. 
Specific aims are described below: 
 
1. ADAMTS13-related assays at different times of the disease clinical course have been evaluated 
for the prediction of clinical outcomes in TTP (death, response to plasma exchange and disease 
recurrence). Severe ADAMTS13 deficiency has been shown to be predictive for recurrence both 
at presentation and during remission. The predictive value of anti-ADAMTS13 antibodies, 
inhibitory activity and immunoglobulin (Ig) class subtype for disease recurrence is still to be 
firmly established. Based on these data, we analyzed, during both conditions, the acute and the 
remission phase, all the biomarkers associated with ADAMTS13 (activity, antigen and class, 
subclass and titre of anti-ADAMTS13 autoantibodies) in acquired TTP patients referred to our 
centre and we correlated them to episode severity and recurrence. The aims of the study were to 
verify if any of the investigated biomarkers could be of prognostic value on the long- and on 
short-term and to identify differences between subgroups of patients that could allow us to 
focus resources on patients at higher risk of recurrence. 
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2. Anti-ADAMTS13 neutralizing autoantibodies can be titrated in vitro using mixing studies of 
heat-inactivated patient and pooled normal human plasmas (NHP) at 1:1 dilution. Reported 
inhibitor assays are far from being optimized and use several different experimental conditions. 
This lack of standardization may in part explain the conflicting results obtained in studies 
assessing the clinical utility of ADAMTS13 inhibitors testing. With this background, the aim of this 
study was to compare CBA and FRET assay for the measurement of ADAMTS13 inhibitors. 
 
3. Collagen binding assay (CBA) and fluorescence resonance energy transfert (FRET) assay are two 
of the most widely used methods for the measurement of ADAMTS13 activity. CBA and FRET 
assays differ for the substrate used (full-length VWF VS VWF73 peptide), for the use of 
denaturing agents (urea VS none) and for the detection method (indirect detection of cleavage 
products through absorbance measurement VS direct detection of cleavage products through 
fluorescence measurement). In comparative studies, these two assays showed a good 
correlation, although relevant discrepancies that might lead to misdiagnosis, have been reported 
in about 10% of TTP samples. So far, the cause for the observed discrepancies is unknown, but a 
role of anti-ADAMTS13 antibodies has been suggested.  
Based on these results, we decided to investigate whether the CBA or the FRET assay results 
reflect the real ADAMTS13 activity level in vivo in a discordant group of samples from acquired 
TTP patients. The experimental conditions were evaluated as possible causes of the reported 
discrepancies. The goal of this study was to determine which assay can be considered the most 
reliable in clinical practice.  
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1. SUMMARY 
Background. Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening disease. Of 
surviving patients, 45% develops an exacerbation or a late recurrence. Severe ADAMTS13 deficiency, 
both during the acute episode and remission is a well-established predictor of recurrence. The 
predictive value of anti-ADAMTS13 antibodies, their inhibitory activity and Ig class subtype for 
disease recurrence is still to be established.  
Objectives. To analyze ADAMTS13 related biomarkers (ADAMTS13 and anti-ADAMTS13 
immunoglobulins, classes and subclasses) and their potential relationship with prognosis. 
Patients/Methods. In 115 patients with TTP we assessed the association between levels of these 
biomarkers and the severity of acute episodes; we analyzed also the hazard ratio and 95% confidence 
interval of recurrence in association with biomarkers levels retrieved at the previous acute episode 
or during remission, using Cox regression models.  
Results. During the acute phase, higher IgA, IgG1 and IgG3 titres showed the strongest association 
with acute episode severity. In the survival analyses the only biomarker significantly associated with 
a high hazard of recurrence following an acute episode was presence of IgG. Conversely, low 
ADAMTS13 activity or antigen levels (<10%), presence of ADAMTS13 inhibitor or IgG during remission 
were all significantly associated with a higher hazard of recurrence. 
Conclusions. Both the Ig class and subclass are of predictive value for acute episode severity in 
patients with TTP. Although markers that could predict the risk of recurrence in the acute phase are 
limited, a thorough assessment of ADAMTS13 related parameters during remission is warranted. 
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2. INTRODUCTION 
Thrombotic thrombocytopenic purpura (TTP) is a rare (annual incidence 5-10 per million) life 
threatening disease characterized by widespread hyaline thrombi, composed primarily of platelets 
and rich in von Willebrand factor (VWF), accompanied by variable fibroblastic infiltration and 
endothelial overlay. It manifests in the terminal arterioles and capillaries of multiple organs, most 
extensively in the heart, brain, kidney, pancreas, spleen, mesentery and adrenal gland (1, 2). The 
disorder is associated with a severe deficiency of the VWF-cleaving protease ADAMTS13 causing 
persistence of highly adhesive ultra-large VWF (ULVWF) (3-7). Within the microcirculation unfolded 
ULVWF multimers spontaneously seize platelets and promote platelet thrombi formation, eventually 
leading to life-threatening microvascular thrombosis and the clinical manifestations typical of TTP. In 
patients with acquired TTP, a deficiency of ADAMTS13 is caused by auto-antibodies against 
ADAMTS13 (3-7). Neutralizing antibodies that inhibit proteolytic activity (6, 7) but also non-
neutralizing antibodies that may enhance clearance or disturb interaction with physiologic binding 
partners have been described (8). In most cases, anti-ADAMTS13 autoantibodies are of the IgG 
isotype, with IgG4 as the most prevalent subclass followed by IgG1 (9, 10). IgM and IgA 
autoantibodies have also been identified (8). 
The currently accepted definition of TTP is based on clinical criteria only and requires the presence of 
mechanical hemolytic anemia with fragmented erythrocytes and thrombocytopenia (platelet count 
<100 x109/L) without alternative causes (11). This is frequently accompanied by symptoms such as 
fever, neurological abnormalities and renal impairment, but since these are not invariably present 
they are not part of the defining symptoms. Note that low levels of ADAMTS13 are also not part of 
the definition and, indeed, are not always observed. 
Demographic studies have shown a preponderance of women (2- to 3-fold risk compared to males) 
and black race (9-fold risk compared to whites) (12). Without timely intervention, TTP is nearly 
always fatal; however, plasma exchange treatment has dramatically decreased the mortality rate to 
10-20%. Exacerbation within 30 days of remission occurs in 22 to 45% of patients, and late 
recurrences (after 30 days) have been reported in 13 to 40% of cases (13-16). Most recurrences occur 
during the first year, but they have also been documented up to 13 years after the first acute event 
(14, 17-21). 
After identifying the diagnostic utility of ADAMTS13 to characterize TTP patients among other 
thrombotic microangiopathy (5, 6, 13, 22-29), several studies assessed the potential utility of 
ADAMTS13-related laboratory measurements at different stages of the disease clinical course for the 
prediction of clinical outcomes in TTP (death, response to plasma exchange and disease recurrence) 
(10, 30-36). Although both low ADAMTS13 activity and antigen level were associated with higher 
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disease mortality (33, 35), data on anti-ADAMTS13 inhibitor levels are contradictory (31, 33). Patients 
with severe ADAMTS13 deficiency at presentation often develop recurrent disease, whereas patients 
without severe deficiency rarely relapse (33). Severe ADAMTS13 deficiency during remission has also 
been shown to be predictive of recurrence (30-32), although some studies did not observe a similar 
association (33). The predictive value of anti-ADAMTS13 antibodies, their inhibitory activity and Ig 
class subtype for disease recurrence is still to be established. Some authors (32) reported that the 
presence of anti-ADAMTS13 antibodies and the titer of ADAMTS13 inhibitor were predictive of 
recurrent disease, others (30) did not observe such an association. Recently, Ferrari and colleagues 
(10) reported an association between anti-ADAMTS13 IgG subclass 4 and recurrent disease. Factors 
that would allow to predict a diagnosis of an isolated or a recurrent form of TTP are thus not well 
established. 
In this multicenter study, we analyzed the association between ADAMTS13-related biomarkers and 
acute episode severity as well as risk of recurrence in patients with TTP. 
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3. MATERIALS AND METHODS 
3.1. Patients and definition of clinical categories 
Clinical centers from seven countries (Italy, Hungary, Lebanon, Romania, Slovenia, Serbia and Russia) 
that manage patients diagnosed with TTP participated in the study. In the frame of an international 
collaborative study the centers collected clinical information in local registries and stored plasma 
samples, during the acute TTP episode and during remission, pertaining to the years 1994-2010. The 
centers provided the Milan Hemophilia and Thrombosis Center (core center) with information on the 
clinical and laboratory data (plasma samples) of these patients, using a specially-tailored collection 
form. 
The local ethical committees in each center approved the study and all patients or their legal 
guardians gave written informed consent. The original diagnosis of an acute TTP episode was 
considered confirmed when at least three of the following criteria were met: thrombocytopenia 
(<150 x109/L) with no other apparent cause, Coombs-negative hemolytic anemia with schistocytes in 
the blood smear, high (>2 standard deviations over the upper limit) serum levels of lactate 
dehydrogenase and signs and symptoms compatible with organ ischemia, mainly but not exclusively 
in the central nervous system. Alternative diseases that may present with similar signs and symptoms 
– such as the enterohemorrhagic form of the hemolytic uremic syndrome, the catastrophic 
antiphospholipid syndrome, disseminated intravascular coagulation, pre-eclampsia and related 
syndromes, collagen vascular diseases, metastatic cancer and Evans’ syndrome – were excluded 
using currently accepted clinical and laboratory criteria (37). Data of all patients were included in a 
digital database (URL: http://www.ttpdatabase.org). 
The first acute TTP episode was classified as secondary when associated with one or more of the 
following conditions: (i) pregnancy/postpartum, (ii) use of drugs reported to be associated with TTP, 
(iii) additional disease associated with TTP (autoimmune diseases or human immunodeficiency virus 
infection). Patients who did not fit the aforementioned categories were classified as having idiopathic 
disease (38). Patients were classified as in remission when they became free of symptoms and had 
normal laboratory values (except for ADAMTS13 levels) for at least 30 days from the conclusion of 
plasma therapy (22). Acute episode severity was assessed in terms of platelet counts and the number 
of plasma exchanges required to achieve remission based on previous studies (38) and in light of the 
observation that lower platelet counts are associated with consumption of VWF multimers in acute 
TTP (39). This would also facilitate comparison with previous studies evaluating the prognostic values 
of ADAMTS13-related biomarkers (36). Recurrence was defined as the re-emergence of clinical 
symptoms or laboratory criteria compatible with a diagnosis of an acute TTP episode (as described 
above) occurring at least 30 days or later after remission of the preceeding acute episode (32). 
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3.2. Samples collection 
Venous blood samples for the measurements of ADAMTS13 (activity and anti-ADAMTS13 antibodies) 
were collected into evacuated tubes containing 0.109 M trisodium citrate at concentration 9:1 as 
anticoagulant. Blood was then centrifuged at 4000 x g for 20 min at 4°C and plasma samples were 
stored in aliquots at -80°C. Samples available for this study were collected for events occurring form 
the year 2000 onwards, with 90% of samples being collected from 2005 onwards. All patients in this 
study had at least one sample retrieved. No more than one sample per patient was collected during 
the same acute event or remission period for an individual patient, although patients had multiple 
samples collected from different acute events or remission periods throughout the study window. All 
ADAMTS13-related measurements were performed at a central laboratory, the Milan Hemophilia 
and Thrombosis Center, within one month of blood collection. 
3.3. ADAMTS13 activity 
ADAMTS13 activity was measured using the residual VWF collagen binding activity (CBA) assay, as 
previously reported (32) with minor modifications: serially diluted pooled normal human plasma 
(NHP) and plasma samples were diluted 1:10 in assay buffer and incubated 1:1 with VWF substrate, 
in a final volume of 100 µL. A detailed description of the assay is provided in chapter IV, paragraph 
3.5. 
Our most recent laboratory evaluation of assay reproducibility yielded an intra-assay coefficient of 
variation of 9% and an inter-assay coefficient of variation of 12%. The lower limit of sensitivity was 
6% of protease levels in NHP taken as the reference standard. The lower value of the reference 
interval (45%) was set at the 5th percentile of the distribution of the values obtained in 72 healthy 
individuals. Severe ADAMTS13 deficiency was arbitrarily considered as levels of 10% or less of 
ADAMTS13 activity in plasma. Previous in vitro experiments showed that, using this assay, high 
plasma levels of VWF do not influence the measurement of ADAMTS13 activity to a major degree 
(40). 
3.4. ADAMTS13 antigen 
ADAMTS13 antigen levels were measured by an ELISA method previously described by Feys and 
colleagues (41) with minor modifications (32). The murine monoclonal anti-ADAMTS13 antibody 
20A5 was used to immobilized the plasma protease on a microtitre plate. Bound ADAMTS13 was 
detected by using the biotinylated anti-ADAMTS13 monoclonal antibody 19H4 and peroxidase-
labelled streptavidin (Roche Mannheim, Germany). Test plasmas (1/2-1/4) and NHP (1/2 to 1/32) 
were diluted in phosphate buffered saline (PBS), pH 7.4. ADAMTS13 antigen values were expressed 
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as percentage of NHP. The lower limit of detection was 1.6% of the reference standard, the intra- and 
inter-assay coefficient of variations were 4% and 8% respectively. The lower limit of the normal 
laboratory range was 45%. 
3.5. Anti-ADAMTS13 inhibitory activity 
Anti-ADAMTS13 inhibitory activity was measured by a CBA-based mixing assay as previously reported 
(32). Heat-inactivated (1 hour incubation at 56°C) patient plasma and pooled NHP were mixed at 1:1 
dilution  and incubated for 2 hours at 37°C. ADAMTS13 residual activity was measured using CBA as 
described above. Anti-ADAMTS13 inhibitor titre was considered positive when the residual activity of 
ADAMTS13 in heat-inactivated patient plasma and NHP mixture was less than 50% of that in the 
control mixture (a 1:1 mixture of buffer and NHP). The inhibitor concentration that neutralized 50% 
of ADAMTS13 activity in an equal volume of NHP was defined as 1 BU mL-1. 
3.6. Anti-ADAMTS13 antibody detection by ELISA 
The ELISA method was performed as previously reported (42) with minor modifications. A 96-well 
plate was coated with mouse anti-V5 antibody (Invitrogen, Grand Island, NY, USA) at 4 μg/ml final 
concentration, overnight at 4°C. After blocking with phosphate-buffered saline (PBS), pH 7.4, 
containing 3% skimmed milk powder, the plate was incubated with cell-culture conditioned media 
containing recombinant V5-tagged ADAMTS13 at a final concentration of 1 μg/ml, followed by 
incubation with plasma samples at various dilutions (1/50, 1/100 and 1/200). For each dilution a 
blank was performed using assay buffer (PBS, pH 7.4, containing 2.5% skimmed milk powder) instead 
of cell-culture conditioned media. Bound antibodies were detected with a sheep HRP-labeled 
anti-human IgG/IgA/IgM/IgG1,2,3,4 and OPD as substrate. Incubation steps were performed at 37°C 
for 1 hour, washing the plate with PBS, pH 7.4, containing 0.1% (v/v) Tween-20 between each step. 
The optical density (OD) values were read at 492 nm using a reference filter at 620 nm in a Multiskan 
Ascent spectrophotometer (Thermo Labsystems, Thermo Electron Corporation, Finland). For IgG, 
after subtracting the blank OD values, the amount of anti-ADAMTS13 autoantibodies was calculated 
against a reference curve made of serial dilutions of a high inhibitor titre patient plasma, arbitrarily 
set as 100%.  
Normal range was calculated on 40 normal plasmas and values higher than 2 standard deviations 
were considered positive (IgG>1.18%; IgA>0.014; IgM>0.034; IgG1>0.006; IgG2>0.013; IgG3>0.019; 
IgG4>0.003). 
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3.7. Normalization of the absorbances measured in IgG subclass ELISA 
To normalize the OD values in patients with more than one IgG subclass of anti-ADAMTS13 
autoantibodies, a normalization procedure was applied as previously described by Ferrari and 
colleagues (10) with minor modifications. 
Purified human IgG 1-4 (lambda chain, Sigma-Aldrich, St Louis, MO, USA) antibodies were coated on 
an ELISA plate in a concentration range of 0.125–1 μg/ml and the OD values generated from the 
addition of HRP-anti-human IgG 1-4 were recorded every 5 min up to 75 min. For each IgG subclass 
and concentration, five independent experiments were performed and the means of the 
corresponding OD values were plotted against time and analyzed by linear regression for each IgG 
subclass. The regression coefficients obtained at a coating concentration of 0.5µg/ml (linear range) 
were used to calculate the OD value of each subclass. Setting the OD value of IgG4 to 1, the resulting 
normalization factors were 1.1, 0.94, 1.49 for IgG1, IgG2 and IgG3, respectively. OD values of TTP 
patients positive for anti-ADAMTS13 IgG subclasses were normalized by multiplying them by the 
corresponding normalization factor. 
To obtain the IgG subclass percentage distribution in a single patient, positive normalized OD values 
of each subclass were summed and the relative proportion of each individual subclass was calculated 
as a percentage of the total absorbance (set at 100%). 
3.8. Statistical analysis 
To take into account the intra-individual correlation of repeated measurements over time, linear 
regression random intercept models (43) were fitted to assess the association between levels of 
ADAMTS13 and anti-ADAMTS13 immunoglobulins and the severity of acute episodes, defined on the 
basis of platelets counts and on the number of plasma exchanges required to achieve remission. 
Values below the limit of detection (LOD) were assigned a value equal to 50% of the LOD. When 
necessary, the dependent variables were transformed (logarithm or square-root) to get a normal 
distribution. 
Using Cox regression models we analyzed the hazard ratio (HR) and 95% confidence interval (95% CI) 
of recurrence in association with levels of ADAMTS13 and anti-ADAMTS13 immunoglobulins 
retrieved at the previous acute episode or during remission. In these analyses, we categorized CBA 
levels and other biomarkers and immunoglobulins in two (low, high) according to standard 
thresholds. To take into account within-subject correlation frailty models were fitted (44). Two 
separate analyses were performed, for measurements during acute episode admissions and 
remission visits, respectively. All the analyses were performed with Stata, version 11 (StataCorp LP, 
College Station, TX, USA). 
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4. RESULTS 
We identified 166 patients with a confirmed diagnosis of TTP over the study period (1994-2010). We 
excluded 11 patients with congenital TTP and 40 patients with plasma samples that were inadequate 
for analysis (gathered during plasma therapy), leaving 115 patients for this analysis.The general and 
clinical characteristics of the patients are summarized in Table 1. 
 
N   115  100% 
Geographic Origin       
Italy   92 80% 
Other Country   23 20% 
Sex      
Male   25 22% 
Female   90 78% 
Age at first acute episode, years      
<20   9 8% 
20-30   26 23% 
30-40   33 28% 
40-50   17 15% 
50-60   19 16% 
60-70   10 8% 
>70   2 2% 
Died from the disease   7 6% 
Idiopathic disease   92 80% 
Secondary disease   23 20% 
other autoimmune disease   4 3% 
Pregnancy   9 8% 
Ticlopidine use   4 3% 
Surgery   3 3% 
Herpes Virus Infection   2 2% 
Malignant disease   1 1% 
ADAMTS13 activity at acute episode 
(n=62) 
idiopathic Secondary Total  
<10 34 9 43 69% 
≥10,<46 9 5 14 23% 
≥46 1 4 5 8% 
 
Table 1. Characteristics of patients. 
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Of the 115 patients, 54 entered the study (first sample retrieved) with an acute TTP episode. Among 
these, 43 entered the study with a first acute TTP event and were followed from then; of them, 7 
developed at least one recurrent event during follow-up. Eleven patients entered the study with a 
recurrent acute TTP event and were followed from then; of them 3 developed at least one 
subsequent recurrent event. The remaining patients (n=61) had their first samples retrieved during 
remission and were followed up from then; of them, 20 had at least one subsequent acute episode of 
TTP (Figure 1). Moreover, 9 patients (8%, 7 women and 2 men, aged 21-66 years, mean age 46 years) 
died during the study period. Of these, 7 died during an acute episode of TTP. The remaining two 
were a 34-year-old female patient who died of a cerebral tumor; and a 54-year-old female patient 
who died of an unknown cause. 
 
54 patients enrolled at acute episode 61 patients enrolled during remission 
 
 
4 patients dead 
 
 
2 patients dead 
  
10 patients recurrent (1 pt dead after 
recurrence) 
  
20 patients recurrent (2 pts dead after 
recurrence) 
  5 patients lost to follow up   6 patients lost to follow up 
35 patients in remission during follow up (at least 
24 months) 
33 patients in remission during follow up (at 
least 24 months) 
Follow-up time: median 5.8, mean 7.3, 
max 32.8 years 
 
Follow-up time: median 3.4, mean 3.8, max 10.5 
years 
Follow up 
summary 
(number of 
patients) 
lost to follow up 11   
Died at first episode 4   
no recurrence 70   
one recurrence 20   
two recurrences 6   
three recurrences 2   
five recurrences 1   
six recurrences 1   
Total 115   
 
Figure 2. Information on study entry and follow-up. 
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4.1. Acute phase analysis 
Data from 62 patients were available for acute phase analysis. During the acute phase, higher IgA 
titres were associated with lower platelet counts, while  higher IgG titres were associated with an 
increased number of plasma exchanges required to achieve remission. Among the IgG subclasses, 
IgG1 had the strongest association with platelet count, while IgG3 was strongly associated with both 
platelet count and the number of plasma exchanges (Table 2). There was no association between 
severity of the acute phase and ADAMTS13 antigen, activity, or inhibitor levels. 
 
 
Log Platelet count √Plasma exchange 
Slope 95% CI p* Slope 95%CI p* 
ADAMTS13 
activity 
0.005 -0.001  0.011 0.12 0.005 -0.021  0.031 0.73 
ADAMTS13 
antigen 
0.003 -0.002  0.008 0.27 0.007 -0.010  0.024 0.43 
Inhibitor 0.003 -0.0001  0.005 0.06 0.006 -0.003  0.017 0.17 
IgG -0.0005 -0.002  0.001 0.42 0.005 0.0002  0.010 0.04 
IgM -0.188 -0.657  0.280 0.43 0.71 -0.796  2.218 0.36 
IgA -0.262 -0.480  -0.045 0.018 0.59 -0.501  1.675 0.29 
IgG1 -0.708 -1.197  -0.218 0.005 1.47 -1.021  3.964 0.25 
IgG2 -0.096 -1.266  1.075 0.87 0.63 -3.034  4.301 0.74 
IgG3 -0.478 -0.817  -0.139 0.006 2.55 0.005  5.095 0.05 
IgG4 0.069 -0.073  0.212 0.34 0.21 -0.565  1.740 0.38 
*p-values from random effect models 
 
Table 3. Cox regression analysis of hazard of recurrence in relation to biomarkers levels at previous acute 
episode. 
 
4.2. Survival analyses 
Data on the number of patients with samples available for survival analysis according to biomarker 
measurements are found in Tables 3 and 4. Patients with low levels of ADAMTS13 (<10%) during the 
acute TTP episode did not have a significantly higher hazard of recurrence, but none of 5 patients 
with normal levels (≥46%) developed recurrences. Patients with presence of IgG during the acute TTP 
episode had a high risk of recurrence (15/50=30%) although hazard ratio was not estimable (none of 
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10 patients with absence of IgG developed recurrence) (Table 3). Analyses considering patients who 
entered the study with a ‘first’ acute TTP episodes led to the same results.  
Patients with low ADAMTS13 activity (<10%) or presence of IgG during remission had a five-fold 
increased hazard of recurrence (respectively HR=4.89, 95% CI 2.00 to 11.99 and HR=4.99, 95% CI 2.08 
to 12.00) (Table 4). Moreover, low ADAMTS13 antigen (<10%) and presence of inhibitor in blood 
drawn during remission were associated with a high hazard of recurrence (respectively HR=5.66, 95% 
CI 2.10 to 15.24 and HR=4.30, 95% CI 2.00 to 9.21) (Table 4).  
 
 No. patients 
No. patients 
with 
recurrences 
Hazard Ratio 95% CI p-value 
ADAMTS13 activity (%)  
   ≥10 71 18 1.00 (ref) 
   <10 19 9 4.89 2.00-11.99 0.001 
ADAMTS13 antigen (%)  
  ≥10 77 19 1.00 (ref) 
  <10 5 3 5.66 2.10-15.24 0.001 
Inhibitor (U/ml)  
   Absent 43 9 1.00 (ref) 
   Present 13 9 4.30 2.00-9.21 <0.001 
IgG (%)  
  ≤1.18 50 7 1.00 (ref) 
  >1.18 26 11 4.99 2.08-12.00 <0.001 
IgM  
  ≤0.034 74 16 1.00 (ref) 
  >0.034 2 2 2.67 0.39-18.44 0.32 
IgA  
  ≤0.014 59 16 1.00 (ref) 
  >0.014 16 1 0.30 0.07-1.27 0.10 
IgG1  
  ≤0.006 25 6 1.00 (ref) 
  >0.006 17 6 1.29 0.61-2.71 0.50 
IgG2  
  ≤0.013 30 6 1.00 (ref) 
  >0.013 12 6 1.85 0.86-3.98 0.12 
IgG3  
  ≤0.019 29 7 1.00 (ref) 
  >0.019 13 5 1.45 0.59-3.58 0.42 
IgG4  
  ≤0.003 11 2 1.00 (ref) 
  >0.003 31 10 1.49 0.49-4.49 0.48 
*Calculated with Cox frailty models to take into account within-subject correlation. 
Table 4. Cox regression analysis of hazard of recurrence in relation to biomarkers levels at previous remission 
observation.  
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5. DISCUSSION 
In recent years, several studies have investigated the role of biomarkers in predicting recurrence of 
episodic autoimmune disease. Particularly meaningful in this respect are studies about the 
distribution of the specific Ig subclasses (studied also in relation to a number of autoimmune diseases 
such as lupus erythematodes (45), rheumatoid arthritis (46), bullous dermopathies (47), celiac 
disease (48), type I diabetes (49), acquired hemophilia (50), sclerosing pancreatitis, autoimmune 
nephropathy (51), multiple sclerosis (52). These studies showed how each IgG subclass seems to 
have a distinct biologic property with different actions on complement activation and immune 
functions. 
Published data suggest that patients with a reduced ADAMTS13 activity during the acute episode 
have a higher risk of recurrence (33). It has also been demonstrated that a severely reduced 
ADAMTS13 activity is predictive of recurrence even during remission (30-32), although some authors 
failed to observe such an association (33). In the present study conducted on a large number of TTP 
patients, we did not identify a higher hazard of recurrence for patients with severe ADAMTS13 
deficiency (<10% of activity) during the acute phase compared with patients with intermediate or 
normal levels (≥10%), but none of 5 patients with normal levels (≥46%) developed recurrences. 
Conversely, patients with severe ADAMTS13 deficiency during remission had a 5-times higher hazard 
of recurrence (Table 5). 
 
Reference 
Study 
design 
Sample 
size* 
Timing of 
measurement 
Marker Endpoint Result 
This study Cohort 62 Acute TTP ADAMTS13 
activity 
Acute episode 
severity 
No association 
59 Acute TTP ADAMTS13 
antigen 
Acute episode 
severity 
No association 
56 Acute TTP Anti-ADAMTS13 
inhibitor level 
Acute episode 
severity 
No association 
52 Acute TTP Anti-ADAMTS13 
Ig class 
Acute episode 
severity 
Higher IgG and IgA titres 
associated with more 
severe acute episode 
47 Acute TTP Anti-ADAMTS13 
IgG subclasses 
Acute episode 
severity 
Higher IgG1 and IgG3  
titres associated with 
more severe acute 
episode 
62 Acute TTP ADAMTS13 
activity 
Recurrence No recurrence in patients 
with ADAMTS13 ≥46% 
62 Acute TTP ADAMTS13 
antigen 
Recurrence No association 
62 Acute TTP Anti-ADAMTS13 
inhibitor 
Recurrence No association 
52 Acute TTP Anti-ADAMTS13 
Ig class 
Recurrence Presence of IgG 
associated with 
recurrence 
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47 Acute TTP Anti-ADAMTS13 
IgG subclasses 
Recurrence No association 
106 Remission ADAMTS13 
activity 
Recurrence ADAMTS13 activity <10% 
associated with 
recurrence 
101 Remission ADAMTS13 
antigen 
Recurrence ADAMTS13 antigen<10% 
associated with 
recurrence 
68 Remission Anti-ADAMTS13 
inhibitor 
Recurrence Presence of inhibitor 
associated with 
recurrence 
74 Remission Anti-ADAMTS13 
Ig class 
Recurrence Presence of IgG 
associated with 
recurrence 
61 Remission Anti-ADAMTS13 
IgG subclasses 
Recurrence No association 
Coppo et 
al. 2006 
(36) 
Cohort 33 Acute TTP Anti-ADAMTS13 
inhibitor 
Acute episode 
severity 
Presence of inhibitor 
associated with more 
severe acute espidoe  
Ferrari et 
al. 2007 
(31) 
Cohort 35 Acute TTP Anti-ADAMTS13 
inhibitor level 
Acute disease 
mortality 
No association 
35 Acute TTP Anti-ADAMTS13 
Ig class 
Acute disease 
mortality 
High IgA titres associated 
with death 
32 Remission ADAMTS13 
activity 
Recurrence ADAMTS13 activity <5% 
deficiency associated 
with recurrence 
Peyvandi 
et al.  
2008 (32) 
Case-
control 
109 Remission ADAMTS13 
activity 
Recurrence ADAMTS13 activity <10%  
associated with 
recurrence 
77 Remission ADAMTS13 
antigen 
Recurrence No association 
97 Remission Anti-ADAMTS13 
autoantibodies 
Recurrence Presence of antibodies 
associated with 
recurrence 
Jin et al. 
2008 (30) 
Cohort 24 Remission ADAMTS13 
activity 
Recurrence Lower ADAMTS13 
activity associated with 
higher risk or recurrence 
  24 Remission Anti-ADAMTS13 
Ig G 
Recurrence No association 
Ferrari et 
al. 2009 
(10) 
Case-
control 
48 Acute TTP Anti-ADAMTS13 
IgG subclasses 
Acute disease 
mortality 
High IgG1 titres 
associated with mortality 
  48 Acute TTP Anti-ADAMTS13 
IgG subclasses 
Recurrence High IgG4 titres 
associated with 
recurrence 
Kremer-
Hovinga 
et al. 
2010 (33) 
Inception 
cohort 
261 Acute TTP ADAMTS13 
activity 
Acute disease 
mortality 
ADAMTS13 activity <10% 
associated with better 
survival (p=0.11) 
183 Acute TTP ADAMTS13 
activity 
Recurrence ADAMTS13 activity <10% 
associated with 
recurrence  
60 Acute TTP Anti-ADAMTS13 
inhibitor level 
Acute disease 
mortality 
High inhibitor level (≥2 
Bethesda units) 
associated with mortality  
37 Remission ADAMTS13 
activity 
Recurrence No association 
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Zheng et 
al. 2010 
(34) 
Cohort 67 Not specified Anti-ADAMTS13 
autoantibody 
antigen specificity 
Clinical symptoms 
and disease-related 
laboratory 
measurements at 
hospital admission 
Antibodies against 
C-terminal domains 
associated with higher 
platelet counts at 
admission 
Yang et al. 
2011 (35) 
Cohort 40 Acute TTP  ADAMTS13 
antigen 
Acute disease 
mortality 
Lower antigen levels 
associated with mortality 
40 Upon 
response to 
PEX 
ADAMTS13 
antigen 
Sustained remission Higher antigen levels 
associated with sustained 
remission 
*Different analyses had different sample size for some studies. 
TTP, thrombotic thrombocytopenic purpura; Ig, immunoglobulin; PEX, plasma exchange. 
 
Table 5. Studies that investigated ADAMTS13-related measurements in thrombotic thrombocytopenic 
purpura. 
 
 
In patients with acquired idiopathic TTP and in some secondary forms, the deficiency of ADAMTS13 
depends on the presence of anti-ADAMTS13 autoantibodies. The predictive value of disease 
recurrence offered by the presence of anti-ADAMTS13 antibodies, their inhibitory activity, Ig classes 
and subclasses is still controversial. The presence of anti-ADAMTS13 autoantibodies during remission 
is predictive of recurrence (32). However, Jin and colleagues (30) did not find any predictive value for 
the levels of IgG anti-ADAMTS13 measured during remission and the risk of recurrence. Our data add 
to these findings by showing that the presence of anti-ADAMTS13 inhibitors during remission also 
predicts the risk of recurrence. They also confirm, contrary to previous reports (30), that presence of 
anti-ADAMTS13 IgG has a strong  predictive value for recurrence both during acute phase and 
remission. However, we did not find any association between IgG subclasses and recurrence risk, as 
was reported in previous studies (10) (Table 5). 
We did not find an association between ADAMTS13 activity or antigen level and acute disease 
severity in acquired TTP, although both parameters were previously associated with higher disease 
mortality (33, 35). Moreover, we did not observe an association between anti-ADAMTS13 inhibitor 
levels and acute episode severity which is in disagreement with previous reports (36) yet echoes 
others evaluating the outcome of mortality (31). Our study also showed that during the acute TTP 
phase, IgA represented the Ig class which is most strongly associated with the clinical severity of the 
acute episode (estimated by the number of platelets at presentation). IgA could contribute to the 
severity of the clinical manifestations by activating the complement system through the 
mannose-binding lectin pathway, thus increasing the complement-mediated inflammation (53). In 
fact IgA levels have been associated with increase mortality from acute phase TTP (31). In this study, 
we identified that the IgG class and subclasses are also predictive of the severity of the acute TTP 
episode. High IgG titres  were associated with a higher number of plasma exchanges; and of the IgG 
subclasses, IgG1 and IgG3 were the most strongly associated with the clinical severity of the acute 
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phase of disease. In fact high IgG1 levels were previously suggested to increase mortality risk in 
patients with TTP (10). 
Detailed knowledge about the pathogenicity of the different isotypes may be useful to develop 
subclass specific immunoaphereses and immunotherapies capable of redirecting the isotopic switch 
towards less pathogenic isotypes and of blocking complement and inflammatory cell activation by 
acting on specific IgG subclasses, and maybe in the future also useful for immunotolerance therapy 
using recombinant ADAMTS13. 
The main limitation of our study is related to the nature of data retrieval. This is not a formal cohort 
study, since we have identified patients from current local registries and patients records, and there 
is no inception cohort, nor clarity whether over the full period of admissions we have included all 
patients. The patients, referred to a tertiary center from many other regional centers, could be 
representing those with highest severity, or highest recurrence rate. Those with a first event long ago 
who never had a recurrence were less likely to be included than those with a recent recurrence, so 
we may have overestimated recurrence risk. Those who would have had a recurrence but died, were 
also not included. Survival analyses comparing groups by laboratory parameters and acute phase 
analyses, however, were not affected by these limitations. So, while our estimates of the proportion 
of patients with severe disease and the recurrence risk per se may be inaccurate, we believe the 
anlayses that showed a preponderance of specific biomarkers in patients with severe events or 
recurrence is reliable. The large number of patients, given the low incidence of the disease, the 
extended observation time available for most patients and the performance of assays for ADAMTS13 
and related biomarkers in the same center, make these the most precise estimates available. Lastly, 
we used platelet counts and the number of plasma exchanges required to achieve remission as 
markers of acute episode severity to facilitate comparisons with similar studies, and based on 
biological evidence of  increased consumption of VWF multimers associated with low platelet counts 
(36, 38, 39). However, one previous report showed that low platelet counts do not predict response 
to plasma exchange during acute TTP (54). Thus, studies evaluating the association between 
ADAMTS13-related biomarkers and acute episode mortality may provide a more objective 
assessment of the association between ADAMTS13-related biomarkers and acute episode severity. 
In conclusion, we undertook a comprehensive assessment of several biomarkers, retrieved both at 
acute phase and remission, to predict outcomes in patients with TTP. Disease recurrence seems to be 
only associated with the presence of IgG antibodies during the acute phase, while alterations in 
several ADAMTS13-related biomarkers could predict recurrence risk when measured during disease 
remission. Hence, adequate laboratory workup in this setting could help identify patients at risk that 
require closer follow up.  Although the study of IgG subclasses does not seem helpful in predicting 
disease recurrence, its value in identifying the severity of the acute episodes warrants further study. 
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1. SUMMARY 
Background. Acquired thrombotic thrombocytopenic purpura (TTP) is associated with the severe 
deficiency of ADAMTS13 due to neutralizing (i.e. inhibitors) and non-neutralizing anti-ADAMTS13 
autoantibodies. The comparison of different ADAMTS13 activity assays to detect inhibitors has never 
been evaluated. Objectives. To compare the anti-ADAMTS13 neutralizing autoantibodies titre results 
obtained with CBA and FRET assays in a series of plasma samples from acquired TTP patients.  
Samples/Methods. 30 plasma samples from acquired TTP patients were analysed. ADAMTS13 
inhibitor was measured using either CBA and FRET assay after mixing heat-inactivated patient’s and 
pooled normal human plasmas (NHP). ADAMTS13 residual activity was measured under three 
different conditions: CBA was performed after 2 hours of incubation of NHP and patient’s plasma at 
37 °C (condition 1); FRET was performed after 2 hours of incubation of NHP and patient’s plasma at 
37 °C (condition 2) and at 25 °C (condition 3). Results were analysed by the Spearman rank order 
correlation and a p-value ≤0.05 was considered statistically significant.  
Results. Spearman rank order correlation analysis revealed a good agreement between ADAMTS13 
inhibitor titres measured by the CBA method and the FRET assay performed after incubation at 
different temperatures (CBA vs FRET–condition 2, Spearman’s rho=0.92, p<0.0001; CBA vs FRET–
condition 3, Spearman’s rho=0.94, p<0.0001). Interestingly, when plasma ADAMTS13 activity was 
measured under condition 2, pre-incubated NHP showed a decrease of enzyme activity about one 
third compared to non-incubated NHP. By contrast, no difference was observed in both conditions 1 
and 3. 
Conclusion. FRET and CBA-based inhibitor measurement performed similarly. FRET, which is more 
rapid and easier to perform than CBA, could hence be the assay of choice for inhibitor quantification. 
Moreover, incubation between heat-inactivated patient plasma and NHP could be performed at 
25 °C, where ADAMTS13 recovery is maintained. 
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2. INTRODUCTION 
Acquired thrombotic thrombocytopenic purpura (TTP) is associated with the severe deficiency of 
ADAMTS13 due to anti-ADAMTS13 autoantibodies, which have been distinguished in two classes, 
neutralizing (i.e. inhibitors) and non-neutralizing antibodies. Neutralizing autoantibodies inhibit 
ADAMTS13 proteolytic activity (1), while non-neutralizing autoantibodies have been proposed to 
enhance its clearance (1, 2). Anti-ADAMTS13 neutralizing autoantibodies can be titrated in vitro using 
mixing studies of heat-inactivated patient and pooled normal human plasmas (NHP) at 1:1 dilution. 
The measurement of inhibitor titre is of clinical relevance. High inhibitor titres at presentation were 
found to be associated with persistent undetectable ADAMTS13 activity in remission, the latter being 
predictive of relapse at 18 months (3). Recently, a neutralizing autoantibody titre of 2 or more 
Bethesda units per ml (BU mL-1) was found to be associated with lower survival among patients with 
severe ADAMTS13 deficiency (4). The comparison of different ADAMTS13 activity assays to detect 
neutralizing autoantibodies has never been evaluated. The importance to determine which assay at 
which experimental conditions should be used to measure the anti-ADAMTS13 neutralizing 
autoantibodies titre in clinical practice has been recently underlined by Plaimauer et al. The authors 
showed that recombinant ADAMTS13 overrides inhibitory antibodies and normalizes deficient 
ADAMTS13 activity in vitro, proposing recombinant ADAMTS13 as a new therapeutic tool in the 
treatment of acquired TTP patients (5). 
With this background, we compared the anti-ADAMTS13 neutralizing autoantibodies titre results 
obtained with the two most commonly used methods, the residual collagen binding activity (CBA) (6) 
and the fluorescence resonance energy transfer (FRET) assays (7), in a series of 30 plasma samples of 
acquired TTP patients. Because different experimental conditions might influence the performance 
of the test (1, 4, 8), we also assessed FRET inhibitor titration at different temperatures (25 °C and 37 
°C). 
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3. MATERIALS AND METHODS 
3.1. Patient samples 
Thirty citrated plasma samples obtained from patients with acquired TTP, referred to our centre and 
enrolled in the Milan TTP Registry (www.ttpdatabase.org) were analyzed. Samples were collected 
during different stages of the disease: 23 samples on disease remission and 7 samples during the 
acute phase. None of the patients were on plasma therapy at the time of sample collection. The 
study was carried out with patient informed consent on the experimental nature of this study. All 
tested samples presented anti-ADAMTS13 autoantibodies by Western Blot analysis and IgG ELISA 
assay. 
3.2. ADAMTS13 antigen 
ADAMTS13 antigen levels were measured by an ELISA method previously described by Feys and 
colleagues (9) with minor modifications (10). The murine monoclonal anti-ADAMTS13 antibody 20A5 
was used to immobilized the plasma protease on a microtitre plate. Bound ADAMTS13 was detected 
by using the biotinylated anti-ADAMTS13 monoclonal antibody 19H4 and peroxidase-labelled 
streptavidin (Roche Mannheim, Germany). Test plasmas (1/2-1/4) and NHP (1/2 to 1/32) were 
diluted in phosphate buffered saline (PBS), pH 7.4. ADAMTS13 antigen values were expressed as 
percentage of NHP. The lower limit of detection was 1.6% of the reference standard, the intra- and 
inter-assay coefficient of variations were 4% and 8% respectively. The lower limit of the normal 
laboratory range was 45%. 
3.3. Anti-ADAMTS13 antibodies by Western Blot and ELISA 
For Western Blot analysis, HEK293 cells conditioned media containing recombinant ADAMTS13 (100 
ng/lane) was separated by SDS-PAGE and transferred onto a pure nitrocellulose membrane (GE 
Healthcare). After blocking, membranes were incubated with citrate plasma samples (1:100 in TBS, 
5% skimmed milk, 0.05% Tween 20, pH 7.4) and bound anti-ADAMTS13 IgGs were detected using a 
peroxidase-conjugated anti-human IgG antibody (Sigma-Aldrich) and a chromogenic substrate kit 
(Biorad).  
The ELISA method was performed as previously reported (11) with minor modifications. See chapter 
III, paragraph 3.6 for a detailed description of the assay. 
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3.4. Anti-ADAMTS13 inhibitory activity 
Anti-ADAMTS13 neutralizing antibody was titrated measuring ADAMTS13 residual activity in a 1:1 
mixture of heat-inactivated (1 hour incubation at 56 °C) patient plasma and pooled NHP. ADAMTS13 
residual activity was measured using the two different assays under three different conditions: CBA 
was performed after 2 hours of incubation of NHP and heat-inactivated patient plasma mixture at 37 
°C (condition 1); FRET was performed after 2 hours of incubation of NHP and heat-inactivated patient 
plasma mixture at 37 °C (condition 2) and at 25 °C (condition 3). ADAMTS13 residual activity was 
measured against a reference curve of serial dilutions of NHP, using the same preincubation time and 
temperature conditions of the sample mixtures. A non-incubated NHP reference curve is included in 
each assay to verify whether ADAMTS13 activity in preincubated plasma samples is preserved. 
Anti-ADAMTS13 neutralizing autoantibodies titre was considered positive when the residual activity 
of ADAMTS13 in heat-inactivated patient plasma and NHP mixture was less than 75% of that in the 
control mixture (a 1:1 mixture of buffer and NHP). The inhibitor concentration that neutralized 50% 
of ADAMTS13 activity in an equal volume of NHP was defined as 1 BU mL-1. CBA and FRET were 
performed as previously described below.  
3.5. Collagen binding assay (CBA) 
The source of protease substrate was a purified VWF concentrate (Facteur Willebrand Humain Tres 
Haute Purité) provided by “Laboratoire Francais du Fractionnement et des Biotechnologies” (Lille, 
France). After reconstitution, at a concentration of 100U/ml, the product was aliquoted and stored at 
-80°C. After thawing, the VWF concentrated was diluted to a concentration of 3 U/mL in 5 mM 
Tris-HCl (pH 8.3), 5 M urea and incubated for 10 min at room temperature. For digestion of VWF 
substrate, test samples were first diluted 1/10, 1/20, and 1/40 with 2.5 M urea, 5 mM Tris (pH8.3) 
and 1mM Pefabloc SC (Roche,Mannheim, Germany). Then, 50 μL were transferred into a microtitre 
plate and incubated with 8 mM BaCl2 for 60 min at 37° C to achieve partial degradation of 
endogenous VWF. Subsequently, 50 μl of VWF substrate were added to test samples and incubated 
for 20 hours at 25°C. The day after, the incubation mixtures were centrifuged for 3 min at 2500 g, 
and the supernatants were used for the collagen binding assay of digested VWF substrate. Fifty μL of 
pooled normal human plasma (NHP) diluted 1/10, 1/20, 1/40, 1/80, 1/160, and 1/320 in 2.5 M urea, 
5 mM Tris, pH 8.3 were used for the calibration curve. The collagen binding activity of the digested 
VWF substrate was then determined according to a previously described method (6) with minor 
modifications. Forty μL of digested samples were diluted with 160 μL PBS containing 0.5% BSA, 0.05% 
Tween 20, using a microtitre plate (Sterilin). Subsequently, 100 μL of each dilution was transferred 
into wells of a second multiwell plate (CovaLink) precoated with 100 μL human collagen type III (3 
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μg/ml) in PBS overnight at 4°C and blocked with 220 μL of PBS containing 2.5% BSA for 30 min. After 
incubation for 2 h, the bound VWF multimers were incubated for 1 h with 100 μL of a solution of a 
peroxidase-conjugated anti-VWF antibody (dilution 1/4000 in PBS containing 0.5% BSA and 0.05% 
Tween 20). Between each step, the microtitre wells were washed three times with 220 μL PBS. The 
chromogenic reaction was performed by addition of 100 μL of 0.5 mg/ml 1,2- phenylenediamine 
dissolved in 7.6 mM citrate, 13.2 mM Na2HPO4, pH 5.0, containing 0.5 μL/ml 30% (v/v) H2O2. The 
reaction was terminated by addition of 50 μL 3 M H2SO4 and the absorbance was read at 492 nm 
using a referencefilter at 620 nm on Multiskan Ascent spectrophotometer (Thermo Labsystems, 
Thermo Electron Corporation, Finland). ADAMTS13 activity values were expressed as percentage of 
NHP standard curve (100% assigned value). 
Our most recent laboratory evaluation of assay reproducibility yielded an intra-assay coefficient of 
variation of 9% and an inter-assay coefficient of variation of 12%. The lower limit of sensitivity was 
6% of protease levels in NHP taken as the reference standard. The lower value of the reference 
interval (45%) was set at the 5th percentile of the distribution of the values obtained in 72 healthy 
individuals. Severe ADAMTS13 deficiency was arbitrarily considered as levels of 10% or less of 
ADAMTS13 activity in plasma. Previous in vitro experiments showed that, using this assay, high 
plasma levels of VWF do not influence the measurement of ADAMTS13 activity to a major degree 
(12). 
3.6. Fluorescence resonance energy transfer (FRET) assay 
Test plasma samples (1/15 to 1/30) and NHP (1/15 to 1/480) were diluted in 5 mM Bis-Tris, 25 mM 
CaCl2, 1mM Pefabloc SC (Roche,Mannheim, Germany), 0.005% Tween-20, pH 6 and then mixed in a 
96-well white plate (Greiner) with FRETS-VWF73 substrate (Peptide International, Osaka, Japan) at a 
final concentration of 2 μM. Fluorescence was measured every 5 min at 37°C in a Tecan Genios 
spectrofluorimeter (Tecan, Vienna, Austria) equipped with a 340-nm excitation filter and a 450-nm 
emission filter. The reaction rate was calculated by linear regression analysis of fluorescence over 
time from 0 to 60 min. ADAMTS13 activity values were expressed as percentage of NHP standard 
curve (100% assigned value). Assay reproducibility yielded an intra-assay coefficient of variation of 
6% and an inter-assay coefficient of variation of 9.5%. The lower limit of sensitivity was 3% of the 
reference standard, the lower value of the reference interval (45%) was set at the 5th percentile of 
the distribution of the values obtained in 72 healthy individuals. 
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4. RESULTS AND DISCUSSION 
Results of CBA and FRET inhibitor measurements are reported in Table 1. Spearman rank order 
correlation analysis revealed a good agreement between anti-ADAMTS13 neutralizing autoantibodies 
titres measured by the CBA method and the FRET assay performed after incubation at different 
temperatures for all 30 samples (CBA VS FRET–condition 2, Spearman’s rho=0.92, p<0.0001; CBA VS 
FRET–condition 3, Spearman’s rho=0.94, p<0.0001). Since the majority of acquired TTP patients with 
anti-ADAMTS13 neutralizing autoantibodies (around 65% in our registry) present a low titre (less 
than 5 BU mL-1), the correlation between assays in this subgroup of samples was analyzed. The 
Spearman rank order correlation was still significant (CBA VS FRET-condition 2, Spearman’s rho=0.78, 
p<0.0001; CBA VS FRET–condition 3, Spearman’s rho=0.85, p<0.0001). One sample (n. 21) was found 
to be positive for anti-ADAMTS13 neutralizing autoantibodies using either FRET assays, but negative 
using CBA assay. 
When plasma ADAMTS13 activity was measured under condition 2, preincubated NHP showed a 
decrease of enzyme activity about one third compared to non-incubated NHP. By contrast, no 
difference in plasma ADAMTS13 activity level between preincubated and non-incubated NHP was 
observed in both conditions 1 and 3 (Figure 1). To investigate the cause of ADAMTS13 
temperature-dependent stability in our FRET assay, plasma pH was checked. Incubation at variable 
temperatures did not cause any pH variation. Then, a different source of the enzyme was tested. 
Recombinant ADAMTS13 was incubated for 2 hours at 37 °C or 25 °C and residual ADAMTS13 activity 
was measured using FRET assay. After the incubation at both temperatures, no loss of activity was 
observed compared to non-incubated recombinant ADAMTS13. The cause of decreased plasma 
ADAMTS13 activity at 37 °C observed in FRET assay may be due to the effect of the high 
preincubation temperature of plasma using a fluorescence detection based assay. Importantly, the 
anti-ADAMTS13 neutralizing autoantibodies detection by FRET assay was not affected, as 
demonstrated by the correlation analysis (Table 1). Moreover, the similar results  obtained at 37 °C 
and 25 °C suggest that the reaction between ADAMTS13 and anti-ADAMTS13 neutralizing 
autoantibodies is not temperature-dependent in vitro.  
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Table 1. Anti-ADAMTS13 neutralizing antibodies titres in 30 plasma samples as determined by the different 
assays. Values of anti-ADAMTS13 IgGs and ADAMTS13 antigen as determined by ELISA assay and ADAMTS13 
activity as determined by CBA assay are also reported. All samples presented anti-ADAMTS13 autoantibodies 
by Western Blot analysis. 
Sample 
Anti-ADAMTS13 Inhibitor (BU mL
-1
) 
Anti-ADAMTS13 
IgG (%) 
ADAMTS1
3 antigen 
(%) 
ADAMTS1
3 activity 
(%) CBA 37°C 
FRET 
37 °C 
FRET 
25 °C 
≥0.4
a
 ≥0.4
a
 ≥0.4
a
 >1.18
a
 40-155
b
 50-158
b
 
       1 2 1.8 2 6 49 <6 
2 2 2.2 3.9 12 25 <6 
3 12.5 14 22 117 52 <6 
4 16 11 12.5 130 72 <6 
5 2.5 3 2.2 14 43 <6 
6 2.7 4 3.3 21 41 <6 
7 6 5.8 10.5 75 40 <6 
8 1.4 1.5 1.9 16 18 <6 
9 1 2.3 2.2 15 47 <6 
10 1 0.8 0.6 2.8 95 <6 
11 13 25 17 285 29 <6 
12 3 3.5 7 15 40 9 
13 10 13 12 65 63 <6 
14 5.5 5 4 15 176 <6 
15 6 5.8 10 38 55 <6 
16 12.5 12.5 12.5 128 36 <6 
17 0.6 1.1 1.2 18 <1 10 
18 1.1 3.8 3 10 68 <6 
19 2.5 5.2 6 20 20 <6 
20 4 8.3 11 60 102 <6 
21 <0.4 1.6 1.2 2 70 27 
22 1 0.7 1 4.8 53 55 
23 18 20 27 35 14 <6 
24 4.5 5 6 31 52 <6 
25 2 2 2.3 6 82 <6 
26 3 3 4.1 38 59 <6 
27 2 2.5 2.7 18 33 <6 
28 3.7 3.3 3.1 21 33 <6 
29 20 20 28 135 38 <6 
30 3 3.6 4.1 28 97 <6 
       
       Median 3 3.7 4.1 20.5 48 3 
Min 0.2 0.7 0.6 2 0.5 3 
Max 20 25.0 28.0 285 176 55 
       
       
All samples (n=30) 
Rs* 0.92 0.94    
Slope* 1,04 1,26    
y-intercept* 0,72 0,63    
       
       
CBA Inhibitor ≤ 5 BU mL
-1
 
(n=20) 
Rs* 0.78 0.85    
Slope* 1.16 1.61    
y-intercept* 0.46 -0.04    
       
 * Spearman’s rho, slope and y-intercepts of the regression lines between CBA assay and each type of FRET assay. Values 
below the detection limit of 0.4 BU mL
-1
 (ADAMTS13 inhibitor assays), 6% (ADAMTS13 activity assay, CBA) and 1% (anti-
ADAMTS13 IgG ELISA assay) were arbitrarily set to 0.2 BU mL
-1
, 3% and 0.5% for calculations, respectively. Analyses were 
performed using GraphPad Prism 5 software (GraphPad Software, Inc, La Jolla, CA, USA). 
a
 Cut-off value,
 b
 Normal range  
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Figure 3. Representative NHP standard curves obtained by FRET assay. Non-incubated NHP (black), NH 
preincubated for 2 h at 25°C (blue) and NHP preincubated for 2 h at 37°C (red) are depicted.      
 
In conclusion, FRET and CBA-based inhibitor measurement performed similarly. FRET, which is more 
rapid and easier to perform than CBA, could hence be the assay of choice for inhibitor quantification. 
Moreover, incubation between heat-inactivated patient plasma and NHP could be performed at 
25 °C, where ADAMTS13 recovery is maintained. Considering the therapeutic potential of restoring 
the enzyme deficiency in acquired TTP patients (5), the rapid and precise measurement of 
anti-ADAMTS13 neutralizing antibodies would be pivotal for the success of a therapeutic approach 
using recombinant ADAMTS13 to overcome the inhibitory activity of anti-ADAMTS13 neutralizing 
autoantibodies. 
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1. SUMMARY 
Background. Collagen binding assay (CBA) and fluorescence resonance energy transfer (FRET) are two 
widely adopted methods for the measurement of the plasmatic activity of ADAMTS13, the von 
Willebrand factor (VWF) cleaving-protease. Accurately measuring ADAMTS13 plasmatic activity is 
essential in the management of thrombotic thrombocytopenic purpura (TTP), a thrombotic 
microangiopathy (TMA) often characterized by severely reduced ADAMTS13 activity. The finding of 
severely reduced ADAMTS13 activity (activity below 10% of normal) has important prognostic 
implications, being associated with 10-fold increased risk of disease recurrence. Despite a good 
agreement between the two assays in the measurement of normal plasmas, discrepant results have 
been reported in up to 10% of TMA cases. The cause for the observed discrepancies is unknown, but 
it has been suggested that the use of a denaturing agent (i.e. urea) in CBA may dissociate complexes 
between ADAMTS13 and anti-ADAMTS13 antibodies, thus generating spuriously-high ADAMTS13 
activity results. 
Aims. To determine whether FRET or CBA results reflect ADAMTS13 activity level in vivo in samples 
from autoimmune TTP patients with discordant results between the two assays and to evaluate the 
role of denaturing agents in the determination of discrepant results. 
Methods. Twenty discordant samples (FRET <10% and CBA >20%) and 11 concordant samples (FRET 
and CBA <10%) with anti-ADAMTS13 antibodies from patients with autoimmune TTP were selected 
from the Milan TTP Registry (URL:http://www.ttpdatabase.org/). The analysis of the VWF multimeric 
pattern was performed on discordant samples collected during disease remission (13/20). 
ADAMTS13 activity was measured under flow conditions in 10/20 discordant and 4/11 concordant 
samples. FRET assay in presence of urea 1,5 M was performed in 19 discordant and 11 concordant 
samples. 
Results. All discordant samples showed a ratio of high molecular weight VWF multimers higher than 
normal, due to the presence of ultra large VWF multimers. Under flow conditions, all tested samples 
showed reduced ADAMTS13 activity (range: 0%-30%). In FRET experiments performed in presence of 
urea, ADAMTS13 activity levels became detectable and/or overcame the 10% activity cut-off in 11 
out of 19 discordant samples, whereas it remained undetectable in all 11 concordant samples tested 
(Fisher’s exact test, p=0.0016). 
Conclusions. The presence of ultra large VWF multimers and the reduced ADAMTS13 activity 
observed under flow conditions in discordant TTP samples indicate a deficiency of the enzyme, 
supporting FRET over CBA results. This study showed that the presence of urea in CBA could lead to 
spurious and misleading results in measuring ADAMTS13 activity. ADAMTS13 activity assays which do 
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not require any denaturing agents should be considered more reliable when assessing the presence 
of severe ADAMTS13 deficiency in patients with autoimmune TTP.  
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2. INTRODUCTION 
Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening microangiopathy characterized 
by thrombocytopenia, hemolitic anemia and signs and symptoms of ischemic organ dysfunctions due 
to the persistence of highly thrombogenic ultra large (UL) von Willebrand factor (VWF) multimers in 
the microcirculation (1, 2). TTP is associated with the severe deficiency of the VWF-cleaving protease 
ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type 1 motif) (3-5), owing 
to mutations in adamts13 gene (congenital TTP) (6) or to the development of anti-ADAMTS13 
autoantibodies (acquired TTP) (4). In the absence of ADAMTS13, highly adhesive ULVWF, that 
spontaneously aggregate platelets, accumulates promoting platelet thrombi formation and 
eventually leading to the clinical features typical of TTP (2). 
Since the discovery of the molecular mechanisms involved in the pathogenesis of TTP, many assays 
for the measurement of ADAMTS13 activity have been developed (7) and several studies have been 
carried out to assess their performance (8, 9) and utility as diagnostic and prognostic tools in the 
treatment of this disease (10-19). Severe ADAMTS13 deficiency (activity below 10% of normal) has 
been reported to be predictive of a risk for relapse either at the time of the initial episode (11, 14, 
18) and during remission (16, 19, 20). In the recent update of the Oklahoma TTP Registry conducted 
by Kremer-Hovinga et al., relapse rate was shown to be greater among patients with ADAMTS13 
activity <10% at presentation, with an estimated risk for relapse at 7.5 years of 41% (18). In a 
retrospective study conducted on the Milan TTP Registry, patients with severe ADAMTS13 deficiency 
during remission had a 5-times higher hazard of recurrence, compared with patients with ADAMTS13 
activity ≥10% (19) (see chapter III). Therefore, accurately measuring ADAMTS13 plasmatic activity is 
essential in the management of TTP patients. 
Collagen binding assay (CBA) and fluorescence resonance energy transfer (FRET) are two widely 
adopted methods for the measurement of ADAMTS13 activity. CBA and FRET assay differ for the 
substrate used (full-length VWF VS VWF73 peptide), for the use of denaturing agents (urea VS none) 
and for the detection method (indirect detection of cleavage products through absorbance 
measurement VS direct detection of cleavage products through fluorescence measurement). Despite 
a good agreement between the two assays (21, 22), discordant results (severe ADAMTS13 deficiency 
detected by only one of the assays) have been reported in up to 10% of TMA cases (22). The cause 
for the observed discrepancies is currently unknown, but an association with the presence of 
anti-ADAMTS13 antibodies was reported (22). It was speculated that the use of a denaturing agent 
(i.e. urea) in CBA may dissociate complexes between ADAMTS13 and anti-ADAMTS13 antibodies, 
thus generating spuriously-high ADAMTS13 activity results (22). 
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The aim of this study was to investigate whether the CBA or the FRET assays results reflect the real 
ADAMTS13 activity level in vivo in samples from acquired TTP patients with discordant results 
between the two assays and circulating anti-ADAMTS13 antibodies. In order to determine if 
ADAMTS13 activity was indeed suppressed (FRET) or not (CBA), an analysis of the multimeric pattern 
of VWF and the measurement of ADAMTS13 activity under flow conditions were performed. 
Moreover, the role of denaturing agents in the determination of the observed discrepancies was 
evaluated. 
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3. MATERIALS AND METHODS 
3.1. Patients, samples and definition of discrepancy 
A cohort of 372 patients with acquired TTP was retrospectively enrolled in the International Registry 
of TTP (www.ttpdatabase.org) of the Milan Hemophilia and Thrombosis Centre from 1994 to June 
2012. The diagnosis of TTP was made on the basis of previously reported criteria (23). The study was 
carried out with patient informed consent on the experimental nature of this study and after 
approval by the Institutional Review Board of the IRCCS Ca’ Granda, Ospedale Maggiore Policlinico. 
Forty-nine samples with discordant values between CBA and FRET assays and 143 concordant 
samples with severe ADAMTS13 deficiency by both assays were selected for this study. All samples 
were positive for anti-ADAMTS13 antibodies. To define discrepancy, a 10% ADAMTS13 activity level 
was assumed as cut-off, being 10% the plasma level that indicates severely reduced activity (22). 
Samples were considered discordant when ADAMTS13 activity was below 10% using only one of the 
two assays. Conversely, samples were defined concordant when ADAMTS13 activity level was below 
or above 10% by both assays. In our cohort, all discordant samples presented ADAMTS13 activity 
below 10% by FRET and above 10% by CBA. Due to plasma availability, 20 out of 49 discordant 
samples were analyzed for VWF multimers pattern, FRET experiments in presence of urea and for 
ADAMTS13 activity measurement under flow conditions.  
All acute plasma samples were collected before plasma therapy. None of the selected samples 
presented high level of bilirubin that could interfere with FRET assay (24). 
3.2. Sample collection and preparation 
Venous blood samples for the measurements of ADAMTS13 (activity and antigen, anti-ADAMTS13 
antibodies) were collected into evacuated tubes containing 3.2% trisodium citrate at a 9:1 
volume/volume ratio, whereas EDTA was used as anticoagulant to collect samples for the evaluation 
of VWF multimers pattern. Platelet-poor plasma was obtained by centrifugation at 3200 g for 20 
minutes at 4°C, aliquoted and stored at -80°C until tested. A pooled normal human plasma (NHP) 
collected from 70 healthy donors was used as the reference standard. 
For ADAMTS13 activity measurement under flow conditions, citrated patient plasma samples and 
NHP were recalcified by the addition of 25 mM CaCl2. Samples were incubated for 3 h at room 
temperature, centrifuged for 10 minutes at 13000 rpm to remove the clot and diluted in Zn2+ and 
Ca2+-containing Hepes buffered saline (HBS; 50 mM HEPES, 5 mM CaCl2, 1 mM ZnCl2, 150 mM NaCl, 
pH 7.4) buffer at 1:1 v/v. As source of platelets, blood was drawn into acid-citrate dextrose 
anticoagulant from healthy volunteers who gave informed consent. Washed platelets were prepared 
as previously described (25), diluted at a platelet count between 20,000 and 30,000 platelets per µL 
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in Hepes Tyrode’s buffer (137 mM NaCl, 2 mM KCl, 3 mM NaH2PO4, 1 mM MgCl2, 5.5 mM glucose, 5 
mM Hepes, 12mM NaHCO3, pH 7.4) and fluorescently labeled with 200 nM 
3,3’-dihexyloxacarbocyanine iodide (DIOC6, Invitrogen) before flow assay. 
3.3. Endothelial Cell Culture 
Blood outgrowth endothelial cells (BOECs) were isolated from human healthy volunteers and 
characterized by immunofluorescent microscopy as described previously (26, 27). BOECs (split rate 
2–6) were grown on collagen-coated cover slides in EBM-2/EGM-2 culture medium (Lonza, San 
Diego, CA) as reported (26). In brief, nitrogen stored aliquots were quickly defrosted at 37°C and 
transferred into tissue-culture flasks, previously coated with rat tail collagen type I (Becton Dickinson, 
San Diego, CA). The flasks were incubated at 37°C with 5% CO2. After 24 hours, nonadherent cells 
were removed by washing with EBM-2/EGM-2 culture medium (Clonetics, San Diego, CA). Thereafter, 
medium was changed every other day until the isolated BOECs reached near confluency. Cells were 
passed by lifting the cells with 0.05% trypsin (Gibco) and plated onto collagen-coated cover slides for 
flow experiments. 
3.4. Laboratory measurements 
3.4.1. ADAMTS13 activity 
ADAMTS13 activity was measured using three different assays, two performed under static condition 
(CBA and FRET) and one performed under flow conditions (flow-based assay). CBA (16, 28) and FRET 
(22, 29) assays were performed essentially as described with minor modifications. For a detailed 
description of CBA and FRET assay, see chapter IV, paragraph 3.5 and 3.6, respectively. In some FRET 
experiments, urea was added to assay buffer at a final concentration of 1,5 M. After a 2 h incubation, 
FRET assay was performed as described before. Results were expressed as the mean of three 
independent determinations. A plasma sample derived from a healthy donor was used as control in 
each test.  In preliminary experiments, different concentrations of urea ranging from 1 to 2,5 M were 
tested for assay set-up. A final concentration of 1.5 M was chosen for TTP samples testing. For 
statistical analysis, ADAMTS13 activity values measured in presence of urea were considered 
increased compared with those measured in absence of urea according to the following criteria: (1) 
when ADAMTS13 activity became detectable or (2) when ADAMTS13 activity value was equal or 
above 10% (the level assumed to define severe deficiency). 
The flow-based assay was performed as previously reported (25). Briefly, blood outgrowth 
endothelial cells (BOEC) were grown on a collagen-coated coverslip and stimulated with 25 µM 
histamine for 10 min at room temperature. Coverslips were mounted in a parallel-plate flow 
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chamber and perfused with DIOC6-fluorescently labeled washed platelets at a shear stress of 2,5 
dynes/cm2 for 120 s, followed by HBS buffer, NHP or TTP patient plasmas for additional 180 s. The 
formation and disappearance of platelet-decorated VWF strings were monitored in real time using an 
Eclipse TE200 inverted fluorescence microscope (objective 20X, 0.4 NA) (Nikon Instruments, Melville, 
NY) coupled to a Hamamatsu CCD camera (ORCA®-R2, Hamamatsu Photonics, Hamamatsu City, 
Japan). Pictures were taken every 200 ms using the Hokawo software (Hamamatsu Photonics) for 
240 s starting 60 s after the initiation of flow. Endothelial cell-anchored VWF strings were counted 
every 10 seconds and the percentage of remained VWF strings in function of time was calculated. 
ADAMTS13 activity of TTP samples was expressed as the percentage of disappeared VWF strings 
compared with NHP after 240 s of perfusion, after blank (buffer) subtraction. Due to the large 
volume of plasma requested, samples could not be tested more than two times. Results were 
expressed as the mean of two determinations. 
In control experiments, 4 acquired TTP plasma samples collected in the acute phase, with 
undetectable ADAMTS13 activity by both static assays were tested. A plasma sample from a 
congenital TTP patient with undetectable ADAMTS13 activity and antigen levels was also tested. 
3.4.2. ADAMTS13 antigen 
ADAMTS13 antigen levels were measured by an ELISA method previously described by Feys and 
colleagues (30) with minor modifications (16). The murine monoclonal anti-ADAMTS13 antibody 
20A5 was used to immobilized the plasma protease on a microtitre plate. Bound ADAMTS13 was 
detected by using the biotinylated anti-ADAMTS13 monoclonal antibody 19H4 and peroxidase-
labelled streptavidin (Roche Mannheim, Germany). Test plasmas (1/2-1/4) and NHP (1/2 to 1/32) 
were diluted in phosphate buffered saline (PBS), pH 7.4. ADAMTS13 antigen values were expressed 
as percentage of NHP. The lower limit of detection was 1.6% of the reference standard, the intra- and 
inter-assay coefficient of variations were 4% and 8% respectively. The lower limit of the normal 
laboratory range was 45%. 
3.4.3. Anti-ADAMTS13 antibodies by Western Blot and ELISA 
For Western Blot analysis, HEK293 cells conditioned media containing recombinant ADAMTS13 (100 
ng/lane) was separated by SDS-PAGE and transferred onto a pure nitrocellulose membrane (GE 
Healthcare). After blocking, membranes were incubated with citrate plasma samples (1:100 in TBS, 
5% skimmed milk, 0.05% Tween 20, pH 7.4) and bound anti-ADAMTS13 IgG was detected using a 
peroxidase-conjugated anti-human IgG antibody (Sigma-Aldrich) and a chromogenic substrate kit 
(Biorad).  
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The ELISA method was performed as previously reported (31) with minor modifications. See chapter 
III, paragraph 3.6 for a detailed description of the assay. 
3.4.4. Anti-ADAMTS13 antibodies inhibitory activity 
Anti-ADAMTS13 antibodies inhibitory activity was measured by a CBA-based mixing assay as 
previously reported (32). Heat-inactivated (1 hour incubation at 56°C) patient plasma and pooled 
NHP were mixed at 1:1 dilution  and incubated for 2 hours at 37°C. ADAMTS13 residual activity was 
measured using CBA as already described. Anti-ADAMTS13 inhibitor titre was considered positive 
when the residual activity of ADAMTS13 in heat-inactivated patient plasma and NHP mixture was less 
than 50% of that in the control mixture (a 1:1 mixture of buffer and NHP). The inhibitor 
concentration that neutralized 50% of ADAMTS13 activity in an equal volume of NHP was defined as 
1 BU mL-1. 
3.4.5. VWF antigen and multimeric analysis 
VWF antigen (VWF:Ag) was quantified using the commercial Kit “von WILLEBRAND FACTOR Antigen” 
(Instrumentation Laboratory) on the ACL TOP 500 Analyzer (Instrumentation Laboratory). VWF 
multimers were evaluated in samples collected during disease remission, as they are known to be 
consumed in the acute phase (32). The multimeric pattern of VWF molecule was analyzed by sodium 
dodecyl sulfate-agarose gel electrophoresis followed by luminographic visualization as previously 
described (32). Samples were diluted in order to obtain a final VWF antigen concentration of 10% 
and electrophoresis was carried out in 1% high gelling temperature agarose (SeaKem® HGT). After 
electrophoresis, proteins were electrotransferred to an immobilon polyvinylidene fluoride 
membrane (Millipore, Billerica, MA) and multimers visualized using a rabbit polyclonal anti-human 
VWF antibody (Dako Cytomation, Glostrup, Denmark) and a goat anti-rabbit IgG peroxidase 
conjugated antibody (BioRad Laboratories, Hercules, CA). The membranes were stained with a 
luminol-iodophenol solution and the densitometric analysis was performed with Typhoon 8600 
Variable Mode Imager (Image Quant TM Software; Amersham Biosciences, Uppsala, Sweden). 
Quantitative evaluation of multimers distribution was performed according to Budde and 
Scheneppenheim (Rev Clin Exp Hematol. 2001;5:335-68) by dividing the plasma lane from the dye 
front into:  small (1–5), intermediate (6-10) and large (> 10) multimers. Results were expressed as the 
ratio between the proportion of large (or high molecular weight, HMW) multimers in each sample 
and that of the reference pooled normal plasma within the same gel. The normal range for HMW 
multimers ratio in 36 healthy subjects was 0.85-1.21. 
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3.4.6. Statistical analysis 
The Fisher’s Exact test and the Mann-Whitney U-test were used to compare categorical and 
continuous variables in different study groups, respectively. Values below the limit of detection (LOD) 
were assigned a value equal to 50% of the LOD. A P value of 0.05 was considered statistically 
significant. 
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4. RESULTS 
4.1. Discordant samples and anti-ADAMTS13 antibodies measurements 
Over the study period (1994-2012), 569 samples from acquired TTP patients collected during the 
acute phase before plasma exchange or during disease remission were analyzed for ADAMTS13 
activity using both CBA and FRET assays and for the presence of anti-ADAMTS13 antibodies (Figure 
1). Among these, 59 discordant samples (10%) having ADAMTS13 activity <10% by FRET assay and 
>10% by CBA were individuated. The frequency of anti-ADAMTS13 antibodies by Western Blot 
analysis or ELISA was higher in discordant samples compared with concordant samples (47/59 VS 
316/510, p=0.0066), confirming previous observations (22). Anti-ADAMTS13 IgG titres measured by 
ELISA and the presence of anti-ADAMTS13 inhibitors were assessed in 47 discordant samples with 
anti-ADAMTS13 antibodies. The results were compared with those obtained from 143 concordant 
samples with ADAMTS13 antibodies and severe ADAMTS13 deficiency by both CBA and FRET assays. 
Discordant samples presented lower anti-ADAMTS13 IgG titres (Mann-Whitney test, p<0.0001) and a 
lower anti-ADAMTS13 inhibitor frequence (Fisher’s exact test, p<0.0001) compared with concordant 
samples.  
Due to plasma availability, further analysis were performed on 20 discordant samples (Figure 1). 
Laboratory data of the selected samples are reported in Table 1. 
 
 
 
Figure 4. Study flow chart. 
569 samples analyzed by  
CBA and FRET assays
59 discordant samples 
(FRET<10% and CBA ≥ 10%)
510 concordant samples 
(FRET and CBA<10% or FRET and CBA≥10%)
47/59 samples positive 
for anti-ADAMTS13 antibodies
316/510 samples positive 
for anti-ADAMTS13 antibodies
(143 with FRET and CBA<10%)
20 samples selected for further analysis:
 13, VWF multimers pattern
 10, flow-based assay
 19, FRET assay in presence of urea
11 samples selected for further analysis:
 4, flow-based assay
 11, FRET assay in presence of urea
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ADAMTS13 activity measurements 
 
Anti-ADAMTS13 antibodies 
measurements 
VWF measurements 
Patient Sample 
Disease 
phase 
CBA 
(%, 50-158) 
FRET 
(%, 45-138) 
FRET Urea 
(%) 
Flow assay 
(%) 
ADAMTS13:Ag 
(%, 40-155) 
WB 
ELISA 
(%, >1.18) 
CBA-Inhibitor 
(BU/mL, <1) 
VWF:Ag 
(%, 40-169
1
) 
ULVWF 
HMW ratio 
(0.85-1.21) 
A 1 A 21 <3 <3 ND 3 + <1.18 <1 102 NA NA 
B 2 R 21 9 9 ND 28 + 107 <1 98 + 1.52 
C 3 A 22 7 18 ND 24 + <1.18 <1 246 NA NA 
D 4 R 22 5 <3 ND 63 + 10 <1 139 + 1.32 
E 5 R 23 <3 <3 ND 33 + 32 <1 177 + 1.52 
F 6 R 24 <3 5 ND 38 + 7 <1 95 ND ND 
G 7 R 26 7 9 ND 31 + 6 <1 72 + 1.22 
H 8 R 26 6 10 ND 21 + 2.8 ND 162 + 1.46 
I 9 R 28 <3 <3 ND 70 + 6 <1 135 + 1.35 
D 10 R 30 <3 <3 17 54 + 1.2 <1 145 + 1.51 
L 11 A 40 <3 11 19 49 + 11 <1 159 NA NA 
M 12 A 40 <3 9 0 3 + <1.18 <1 209 NA NA 
N 13 R 42 5 5 29 49 + <1.18 <1 158 - 1.27 
O 14 A 48 <3 7 21 64 + <1.18 <1 193 NA NA 
P 15 R 56 <3 ND 14 100 + 6 <1 213 ND ND 
Q 16 R 80 4 30 24 68 - 2.2 ND 105 + 1.43 
Q 17 R 93 <3 30 26 70 - 3 ND 72 + 1.47 
Q 18 R 93 <3 11 23 85 + 3.2 ND 93 + 1.23 
Q 19 R 97 <3 20 12 62 - 1.2 ND 66 + 1.38 
R 20 R 101 5 27 ND 51 + 2 <1 404 + 1.40 
 
Table 1. ADAMTS13 and VWF-related laboratory data of discordant samples from acquired TTP patients. 20 samples (1-20) from 16 patients (A-R; patients D and Q present 
multiple samples) were selected for this study. Samples are ordered according to CBA results, from lowest to highest value. Normal ranges or cut-offs are indicated between 
parentheses. Results of FRET assay that significantly increased in presence of urea (“FRET urea”) are indicated by bold numbers. 
Disease phase: A, acute; R, remission. WB: Western Blot. +, positive; -, negative; ND, not done (due to lack of plasma); NA, not applicable (samples collected at acute phase). 
1 Normal range for individuals with blood group O is reported. Normal range for individuals with blood group non-O was 55%-165%. 
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4.2. Multimeric analysis of VWF 
To investigate which assay results reflect the real ADAMTS13 activity level in vivo (i.e. severely 
reduced activity in case of FRET or moderately reduced to normal activity in case of CBA), the 
multimeric pattern of VWF was evaluated in 13 discordant samples collected during disease 
remission. All tested samples but one (n. 13) presented UL-VWF (Figure 2), indicating a deficiency of 
ADAMTS13. Due to the presence of UL-VWF, densitometric analysis of multimers distribution in 
discordant plasma samples showed a HMW multimers ratio higher than normal range (mean ± SD, 
1.40 ± 0.10; normal range: 0.85-1.21) (Table 2). Despite the absence of UL-VWF, a pathologically high 
HMW multimers ratio (1.27) indicating an abnormal proteolysis of VWF by ADAMTS13 was also 
found in sample n. 13. 
 
Figure 2. Representative pattern of VWF multimers in discordant TTP samples. Lane 1: positive control, 
sample collected during disease remission presenting undetectable ADAMTS13 activity by both assays; lane 2: 
discordant sample n. 8; lane 3: pooled normal human plasma. Low, intermediate, high molecula weight and 
ultra-large VWF multimers are highlighted by parentheses at the right side of the figure. 
 
Among the 13 samples in which VWF multimers pattern was evaluated, sample n. 20 showed an 
extremely high VWF antigen level (404%) (Table 2). In this particular case, the presence of UL-VWF 
Low
Intermediate
High
Ultra-large
21 3
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might be also explained by a massive secretion of VWF, with consequent unbalancement of the 
VWF-ADAMTS13 axes. No clinical data at the time of sample collection was available to explain such 
high VWF antigen value, however the patient died for brain cancer a year later. 
4.3. ADAMTS13 activity assay under flow conditions 
A flow-based assay, in which endothelial cell-anchored VWF strings are used as ADAMTS13 substrate, 
was used to evaluate ADAMTS13 activity in 10 discordant samples (Table 2) and 4 concordant 
samples collected in the acute phase before plasma treatment. In a preliminary set-up series of 
experiments, we determined the disappearance of VWF strings in the presence or absence of NHP, 
by calculating the percentage of remaining strings in function of time. In the presence of buffer 
alone, 91±4% (n=10) of the released VWF strings remained attached to the endothelial surface after 
240 s of perfusion. Conversely, perfusion with NHP resulted in the gradual disappearance of VWF 
strings, 49%±12% (n=11) after 240 s of perfusion. As negative control, a congenital TTP plasma 
sample with undetectable ADAMTS13 antigen and activity was used: 92% of VWF strings persisted 
after 240 s of perfusion, indicating that the VWF strings cleavage was ADAMTS13-specific.  
ADAMTS13 activity of TTP samples was then expressed as the percentage of disappeared VWF strings 
compared with NHP. All samples tested showed reduced ADAMTS13 activity (range: 0%-29%), similar 
to those obtained in concordant samples (range: 0%-16%) (Figure 5). Moreover, all samples, with the 
exception of number 13 (29% activity), presented an ADAMTS13 activity value below that of a 1/10 
mixture of NHP and heat-inactivated NHP (27% activity).  
 
Figure 5. Scatter plot of ADAMTS13 activity values measured under flow conditions. ADAMTS13 activity 
values of concordant samples collected in the acute phase (n=4) and discordant samples (n=10) are depicted. 
Median values are indicated by solid lines. The dashed line indicates the ADAMTS13 activity value obtained 
diluting NHP 1/10 in heat-inactivated NHP (27% of VWF strings disappeared compared with NHP). 
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4.4. ADAMTS13 activity measured by FRET assay under denaturing conditions 
Preliminary experiments were performed to evaluate the influence of different concentration of urea 
on the measurement of ADAMTS13 activity of NHP by FRET assay. Three concentrations of urea were 
tested: 1.5 M, 2 M and 2.5 M (Figure 3). In the presence of 2.5 M urea, which is the concentration 
used in CBA assay to unfold VWF, ADAMTS13 activity was completely abolished. A concentration of 
1.5 M urea, which gave an approximately 30% reduction of ADAMTS13 activity, was chosen for 
further experiments (Figure 3). A normal plasma sample was used as control in each assay. No 
difference was observed in absence and presence of urea (n=6, 128% ± 4% VS 126% ± 4%). 
 
 
 
Figure 3. NHP standard curves obtained by FRET assay in absence (black) and presence of 1.5 M (blue), 2 M 
(red) and 2.5 M (green) urea. 
 
The results of FRET experiments in presence of urea 1.5 M are reported in Table 2 and depicted in 
Figure 4. Under this condition, ADAMTS13 activity levels became detectable and/or overcame the 
10% activity cut-off for severe ADAMTS13 deficiency in 11 out of 19 discordant samples (Table 2, 
bold numbers), whereas it remained undetectable in 11 concordant samples tested for comparison 
(p=0.0016). However, increased ADAMTS13 activity levels in discordant samples were always lower 
than those measured in CBA. This result may depend on the different concentrations of urea used 
(2.5 M in CBA VS 1.5 M in FRET). 
Among discordant samples, 6 derived from the same 2 patients (n. 4, 10, patient D; n. 16-19, patient 
Q). The difference between discordant and concordant samples was still significant when only one 
sample per patient was considered (7/15 VS 0/11, p=0.0103).  
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Figure 4. Paired comparisons of ADAMTS13 activity values measured by FRET assay in absence (-) and 
presence (+) of urea in discordant (left) and concordant (right) samples. Samples with the same ADAMTS13 
activity values are superimposed. A value of half the limit of detection (1.5% activity) has been arbitrarly used 
to depict samples with ADAMTS13 activity values below FRET assay limit of detection (3% activity). 
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5. DISCUSSION 
An ADAMTS13 activity level below 10% of normal, either at acute episode (11, 14, 18) and during 
disease remission (16, 19, 20), is associated with a higher risk of recurrence in TTP patients. Thus, the 
availability of a specific, sensitive and reliable assay for the assessment of ADAMTS13 severe 
deficiency is pivotal for the management of this life-threatening disease. CBA and FRET assays are 
two widely used methods for the quantification of ADAMTS13 activity. The two assays showed a 
good agreement in comparative studies (21, 22), nevertheless important discrepancies have been 
reported in a small but relevant percentage of acquired TTP cases (22). It was suggested that the 
denaturing agent (i.e. urea) required in CBA to unfold VWF, could dissociate 
ADAMTS13/anti-ADAMTS13 antibodies immune complexes, artifactually increasing ADAMTS13 
activity measured in CBA (22). The aim of this study was to investigate whether CBA or FRET assay 
results reflect ADAMTS13 activity in vivo in a large number of discordant samples (FRET <10% and 
CBA ≥10%) presenting anti-ADAMTS13 antibodies and if urea is actually a cause of this phenomenon.  
In order to assess whether ADAMTS13 activity is suppressed (FRET) or not (CBA) in discordant TTP 
samples, the analysis of VWF multimeric pattern and the measurement of ADAMTS13 activity in a 
flow-based assay were performed. All discordant samples collected during the remission phase (13 
out of 18 tested) presented a proportion of HMW VWF multimers higher than normal, due to the 
presence of UL-VWF except for one case. This result indicates a deficiency of the enzyme, as 
demonstrated in a previous study (32). Lotta et al. indeed showed that, during remission, plasma 
from TTP patients with severely reduced ADAMTS13 activity presents a higher ratio of HMW 
multimers compared with patients having normal levels of the metalloprotease, who in turn display a 
HMW multimers ratio similar to that obtained in healthy donors (32). 
In the flow-based assay, secreted UL-VWF multimers are anchored to endothelial cells and stretched 
by flow, which render the VWF scissile bond accessible to ADAMTS13 cleavage. As previously 
reported, this assay may only be reliable in discriminating ADAMTS13 levels higher or lower than 
20%, without measuring a precise value of ADAMTS13 activity (9). Nevertheless, it has the great 
advantage of employing a physiological substrate (full-length VWF) in a physiological environment 
(platelets and endothelial cells on a collagen-coated surface), under physiological experimental 
conditions (flow). In presence of discordant plasmas (n=10, ADAMTS13 activity <10% by FRET and 
>30% by CBA), 0%-29% of VWF strings disappeared (compared with pooled normal plasma). Similarly, 
0-16% of VWF strings disappeared when concordant plasmas with undetectable ADAMTS13 activity 
by both static assays were perfused. Moreover, 9 out of 10 discordant samples presented an 
ADAMTS13 activity value below that of a 1/10 mixture of NHP and heat-inactivated NHP (27% of 
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VWF strings disappeared). Flow-based assay results are consistent with a reduced ADAMTS13 activity 
in discordant samples. 
All together, the analysis of VWF multimeric pattern and the measurement of ADAMTS13 activity 
under flow conditions support FRET over CBA results. Flow-based assay results suggest also that the 
different type of substrate, full-length- (CBA and flow-based assay) or peptide-based (FRET assay) 
VWF, is not the cause of the observed discrepancies, at least in our cohort of samples.  
To investigate the role of denaturing agents, FRET assay was performed in presence of 1.5 M urea. 
Using this modified assay, no difference was observed in concordant samples with undetectable 
ADAMTS13 activity by both CBA and FRET assays. On the contrary, in 50% of discordant samples, 
ADAMTS13 activity levels became detectable and/or overcame the 10% activity cut-off for severe 
ADAMTS13 deficiency, suggesting urea as one of the possible cause of discordant results. 
It was previously speculated that urea may act dissociating the immune complexes formed between 
ADAMTS13 and anti-ADAMTS13 antibodies (22). These immune complexes could vary in terms of 
affinity and/or avidity between different patients or within the same patient during the course of the 
disease. It has been formerly shown that anti-ADAMTS13 antibodies of different Ig class and IgG 
subclass are present in patients with autoimmune TTP and that the prevalence of each Ig 
class/subclass vary between different patients (those experiencing recurrencies and those who do 
not) and between the two phases of the disease (acute and remission) (19, 33). Furthermore, several 
epitope mapping studies showed that anti-ADAMTS13 antibodies target multiple domains of the 
metalloprotease: 97-100% of acquired TTP patients present antibodies against a major epitope in the 
spacer domain of ADAMTS13, however antibodies directed towards the C-terminal domains have 
been described (34-37). Zheng et al. reported that patients whose antibodies bound only to the 
N-terminal domains presented higher IgG titres than patients with antibodies against both the 
N-terminal and the C-terminal domains of ADAMTS13 (36). In another study, Pos et al. reported that 
1% Triton X-100 (a commonly used detergent for solubilizing proteins and reducing non-specific 
interactions) disrupted the binding of anti-ADAMTS13 antibodies to ADAMTS13 C-terminal domains 
(37). These observations suggest that autoantibodies directed towards the C-terminal domains could 
be less affine than those recognizing the spacer domain. On the whole, these data support the 
hypothesis that ADAMTS13/anti-ADAMTS13 antibodies immune complexes with different affinity 
may be present in patients with acquired TTP. In our cohort, the frequency of anti-ADAMTS13 
inhibitors and anti-ADAMTS13 IgG titres were lower in discordant samples compared with 
concordant samples with severe ADAMTS13 deficiency, suggesting that anti-ADAMTS13 antibodies 
with lower affinity/avidity may be present in the first group of samples. Consequently, it is 
reasonable to conclude that urea present in CBA may more easily dissociate such weaker immune 
complexes, thus generating spuriously-high ADAMTS13 activity results. It is as much 
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worth-considering that not all discordant samples tested turned concordant in FRET assay after the 
addition of 1.5 M urea. On the other hand, CBA was performed at a higher concentration of urea, 2.5 
M, which could not be replicated in FRET assay because it completely abolished ADAMTS13 activity. 
This allow us to suppose that the interaction between ADAMTS13 and anti-ADAMTS13 antibodies 
may be variably susceptible to urea and that a concentration of 1.5 M may not be enough to 
dissociate immune complexes of all patients. It is tempting to speculate that the reported 
discrepancies may reflect the complexity and the heterogeneity of the immune response against 
ADAMTS13, which may be rather qualitatively than quantitatively different among TTP patients. The 
future biochemical and functional characterization of purified anti-ADAMTS13 antibodies from 
discordant TTP plasma samples may clarify the molecular mechanism underlying this phenomenon.  
In conclusion, this study showed that FRET rather than CBA results reflect ADAMTS13 activity level in 
vivo in samples with discordant results between the two assays. Moreover, the presence of urea in 
CBA is a likely cause of these discrepancies. FRET assay, despite employing a non-physiological 
peptide-based VWF substrate, should be considered more reliable than CBA in the clinical 
management of acquired TTP patients. In general, the use of an assay which does not require any 
denaturing agents is advised when assessing the severe deficiency of ADAMTS13. 
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CHAPTER VI – CONCLUSIONS 
 
Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening microangiopathic disorder, 
due to the persistence of highly thrombogenic ultra large (UL) von Willebrand factor (VWF) 
multimers in the microcirculation. TTP is associated with the severe deficiency of ADAMTS13 (activity 
<10%), the metalloprotease responsible for the proteolytic regulation of VWF multimers size. In the 
acquired form of the disease, the severe deficiency of ADAMTS13 is caused by anti-ADAMTS13 
antibodies that inhibit ADAMTS13 activity (neutralizing anti-ADAMTS13 antibodies or inhibitors) 
and/or increase its clearance from the circulation (non-neutralizing anti-ADAMTS13 antibodies). In 
the absence of ADAMTS13, highly adhesive ULVWF, that spontaneously aggregate platelets, 
accumulates promoting platelet thrombi formation and eventually leading to the clinical features 
typical of TTP. 
In the past decade, the increasing knowledge regarding the molecular mechanisms involved in the 
pathogenesis of TTP, yielded to a proliferation of assays for the measurement of ADAMTS13 and 
anti-ADAMTS13 antibodies. Despite the numerous studies conducted to assess the clinical utility of 
ADAMTS13-related markers, their prognostic value is still controversial. The finding that severe 
ADAMTS13 deficiency and the presence of anti-ADAMTS13 antibody is associated with an increased 
risk of relapse is rather consistent, but studies on larger cohort of patients are needed. More 
uncertain is the predictive value of  immunoglobulin (Ig) class subtype of  anti-ADAMTS13 antibodies, 
whether or not inhibitory. Controversial results may be partially due to differences in the assays used 
to measure ADAMTS13 activity and anti-ADAMTS13 antibodies, which require further 
standardization.  
The possibility of using ADAMTS13 testing to manage TTP patients depends on ADAMTS13 assays 
becoming widely available, rapid, reliable and feasible for most clinical laboratories. Only a few 
laboratories have acquired sufficient experience in such a rare disease, allowing them to give helpful 
advice to less specialized laboratories. This doctoral thesis has been conducted in one of these 
specialized laboratories. Our research group at The Hemophilia and Thrombosis Centre of Milan has 
indeed an internationally recognized reputation in research and treatment of TTP. An international 
TTP registry, containing information on hundreds of cases of the disease, has been developed and 
curated in our centre. Based on these premises, the research conducted during this doctorate had 
two main objectives: to evaluate, in our large cohort of acquired TTP patients, the clinical utility of 
ADAMTS13-related biomarkers and to investigate which ADAMTS13 assay may be more reliable in 
the management of acquired TTP. 
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In the first part of this study, we analyzed, during both acute and remission phase, all the biomarkers 
associated with ADAMTS13 (activity, antigen and class, subclass and titre of anti-ADAMTS13 
autoantibodies) in acquired TTP patients referred to our centre and we correlated them to episode 
severity and recurrence. We found that both the Ig class and subclass are of predictive value for 
acute episode severity in patients with TTP. Disease recurrence seemed to be associated with the 
presence of IgG antibodies during the acute phase, while alterations in several ADAMTS13-related 
biomarkers (ADAMTS13 activity or antigen levels <10%, presence of ADAMTS13 inhibitor or IgG) 
could predict recurrence risk when measured during disease remission.  
The results of this study confirmed and extended previous data on the prognostic value of 
ADAMTS13 testing, providing valuable information for the identification of patients at higher risk 
requiring closer follow up.  
The studies conducted in the second part of this doctorate intended to investigate the performance 
of two widely used methods, the collagen-binding assay (CBA) and the more recent fluorescence 
resonance energy transfer (FRET) assay, for the measurement of ADAMTS13 activity and 
anti-ADAMTS13 inhibitors. Given the prognostic value of ADAMTS13-related markers (as 
demonstrated in the first part of this thesis), it is essential to determine which ADAMTS13 assay is 
more reliable in the management of patients suffering from this rare but life-threatening disease. 
CBA and FRET assay strongly differ from a methodological point of view: they use different substrates 
(full-length VWF VS peptide VWF), different experimental conditions (urea VS none) and different 
detection methods (indirect detection of cleavage products through absorbance measurement VS 
direct detection of cleavage products through fluorescence measurement). Several studies have 
been performed to evaluate the performance and utility of the two assays for the measurement of 
ADAMTS13 activity, but they have never been compared for the detection of anti-ADAMTS13 
inhibitors in mixing studies. Moreover, despite the good correlation in the quantification of 
ADAMTS13 activity in normal plasmas, important discrepancies have been described in a small but 
relevant percentage of TTP cases.  
First, we decided to compare anti-ADAMTS13 inhibitors titres measured by CBA and FRET assays in 
acquired TTP patients enrolled in the Milan TTP Registry. We found that the two assays performed 
similarly and concluded that FRET, which is more rapid and easier to perform than CBA, could hence 
be the assay of choice for inhibitor quantification. 
Secondly, we investigated whether CBA or FRET assay results reflect ADAMTS13 activity level in vivo 
in samples presenting circulating anti-ADAMTS13 antibodies and discordant results between the two 
assays. We performed an analysis of the multimeric pattern of VWF and measured ADAMTS13 
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activity using an additional assay which employs a full-length VWF substrate under flow conditions. 
We found that FRET assay results, despite the use of a non-physiologic peptide-based VWF substrate, 
more closely resemble ADAMTS13 activity level in these particular group of samples. Moreover, we 
showed that the presence of denaturing agents in CBA is a likely cause of the observed discrepancies. 
On the whole, these findings allow us to affirm that FRET rather than CBA should be considered the 
assay of choice for the measurement of both ADAMTS13 activity and ADAMTS13 inhibitors. 
In conclusion, the research conducted during the doctorate further established the clinical utility of 
ADAMTS13-related assays in acquired TTP and provided methodological guidelines for the choice of 
such assays when assessing the severe deficiency of ADAMTS13 or the presence of anti-ADAMTS13 
inhibitors. 
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SUMMARY 
 
Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening microangiopathic disorder, 
due to the persistence of highly thrombogenic ultra large (UL) von Willebrand factor (VWF) 
multimers in the microcirculation. TTP is associated with the severe deficiency of ADAMTS13 (activity 
<10%), the metalloprotease responsible for the proteolytic regulation of VWF multimers size. In the 
acquired form of the disease, the severe deficiency of ADAMTS13 is caused by anti-ADAMTS13 
antibodies that inhibit ADAMTS13 activity (neutralizing anti-ADAMTS13 antibodies or inhibitors) 
and/or increase its clearance from the circulation (non-neutralizing anti-ADAMTS13 antibodies). In 
the absence of ADAMTS13, highly adhesive ULVWF, that spontaneously aggregate platelets, 
accumulates promoting platelet thrombi formation and eventually leading to the clinical features 
typical of TTP. 
In the past decade, the increasing knowledge regarding the molecular mechanisms involved in the 
pathogenesis of TTP, yielded to a proliferation of assays for the measurement of ADAMTS13 and 
anti-ADAMTS13 antibodies. Despite the numerous studies conducted to assess the clinical utility of 
ADAMTS13-related markers, their prognostic value is still controversial. The finding that severe 
ADAMTS13 deficiency and the presence of anti-ADAMTS13 antibody is associated with an increased 
risk of relapse is rather consistent, but studies on larger cohort of patients are needed. More 
uncertain is the predictive value of  immunoglobulin (Ig) class subtype of  anti-ADAMTS13 antibodies, 
whether or not inhibitory. Controversial results may be partially due to differences in the assays used 
to measure ADAMTS13 activity and anti-ADAMTS13 antibodies, which require further 
standardization.  
With this background, the present research had two main objectives: to evaluate, in a large cohort of 
acquired TTP patients enrolled in the international Milan TTP Registry (developed and curated at the 
The Hemophilia and Thrombosis Centre of Milan), the clinical utility of ADAMTS13-related 
biomarkers and to investigate which ADAMTS13 assay may be more reliable in the management of 
acquired TTP. 
 
In the first part of this study, we analyzed, during both acute and remission phase, all the biomarkers 
associated with ADAMTS13 (activity, antigen and class, subclass and titre of anti-ADAMTS13 
autoantibodies) in acquired TTP patients referred to our centre and we correlated them to episode 
severity and recurrence. We found that both the Ig class and subclass are of predictive value for 
acute episode severity in patients with TTP. Disease recurrence seemed to be associated with the 
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presence of IgG antibodies during the acute phase, while alterations in several ADAMTS13-related 
biomarkers (ADAMTS13 activity or antigen levels <10%, presence of ADAMTS13 inhibitor or IgG) 
could predict recurrence risk when measured during disease remission.  
The results of this study confirmed and extended previous data on the prognostic value of 
ADAMTS13 testing, providing valuable information for the identification of patients at higher risk 
requiring closer follow up.  
The studies conducted in the second part of this doctorate intended to investigate the performance 
of two widely used methods, the collagen-binding assay (CBA) and the more recent fluorescence 
resonance energy transfer (FRET) assay, for the measurement of ADAMTS13 activity and 
anti-ADAMTS13 inhibitors. Given the prognostic value of ADAMTS13-related markers (as 
demonstrated in the first part of this thesis), it is essential to determine which ADAMTS13 assay is 
more reliable in the management of patients suffering from this rare but life-threatening disease. 
CBA and FRET assay strongly differ from a methodological point of view: they use different substrates 
(full-length VWF VS peptide VWF), different experimental conditions (urea VS none) and different 
detection methods (indirect detection of cleavage products through absorbance measurement VS 
direct detection of cleavage products through fluorescence measurement). Several studies have 
been performed to evaluate the performance and utility of the two assays for the measurement of 
ADAMTS13 activity, but they have never been compared for the detection of anti-ADAMTS13 
inhibitors in mixing studies. Moreover, despite the good correlation in the quantification of 
ADAMTS13 activity in normal plasmas, important discrepancies have been described in a small but 
relevant percentage of TTP cases.  
First, we decided to compare anti-ADAMTS13 inhibitors titres measured by CBA and FRET assays in 
acquired TTP patients enrolled in the Milan TTP Registry. We found that the two assays performed 
similarly and concluded that FRET, which is more rapid and easier to perform than CBA, could hence 
be the assay of choice for inhibitor quantification. 
Secondly, we investigated whether CBA or FRET assay results reflect ADAMTS13 activity level in vivo 
in samples presenting circulating anti-ADAMTS13 antibodies and discordant results between the two 
assays. We performed an analysis of the multimeric pattern of VWF and measured ADAMTS13 
activity using an additional assay which employs a full-length VWF substrate under flow conditions. 
We found that FRET assay results, despite the use of a non-physiologic peptide-based VWF substrate, 
more closely resemble ADAMTS13 activity level in these particular group of samples. Moreover, we 
showed that the presence of denaturing agents in CBA is a likely cause of the observed discrepancies. 
On the whole, these findings allow us to affirm that FRET rather than CBA should be considered the 
assay of choice for the measurement of both ADAMTS13 activity and ADAMTS13 inhibitors. 
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In conclusion, the research conducted during the doctorate further established the clinical utility of 
ADAMTS13-related assays in acquired TTP and provided methodological guidelines for the choice of 
such assays when assessing the severe deficiency of ADAMTS13 or the presence of anti-ADAMTS13 
inhibitors. 
 
